COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third programme of EU action in the field of health in 2017
Date: 2020-03-10
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU programme, disease prevention, e-Health, health care, health care system, implementation of the budget, pharmaceutical legislation, programme budgeting, public health

EN 

  EN 

   EUROPEAN COMMISSION  Brussels, XXX  […](2020) XXX draft  COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third programme of EU action in the field of health in 2017  
 
 
Table of Contents 
JOINT ACTIONS ..................................................................................................................................................... 4 

1. 

20122202 — Mental Health and Well-being (MH-WB) Joint Action .............................................................. 4 

2. 
20122103  —  The  impact  on  maritime  transport  of  health  threats  due  to  biological,  chemical 
&radiological agents, including communicable diseases (SHIPSAN ACT Joint Action) ........................................ 5 

3. 

20122201 — Joint Action Health Workforce Planning and Forecasting (JA EUHWF) .................................. 7 

4. 
20112102  —  Achieving  Comprehensive  Coordination  in  Organ  Donation  throughout  the  European 
Union (ACCORD) .................................................................................................................................................... 8 

PROJECTS ............................................................................................................................................................. 11 

1. 

20121205 — Innovating care for people with multiple chronic conditions in Europe (ICARE4EU) ............ 11 

2.  Stimulating Innovation Management of Poly-pharmacy and Adherence in the Elderly (SIMPATHY) ........ 12 

3. 
20121211  —  Benchmark  comprehensive  cancer  care  that  provides  interdisciplinary  treatment  for 
patients, and yield examples of best practice in comprehensive cancer care (BENCH-CAN) ............................... 13 

4. 
20121217 — NEW e-HEALTH SERVICES FOR THE EUROPEAN REFERENCE NETWORK ON 
RARE ANAEMIAS (e-ENERCA) ......................................................................................................................... 15 

OPERATING GRANTS ......................................................................................................................................... 17 

1. 

742885 — Alzheimer Europe (AE SGA 2017) .............................................................................................. 18 

2. 
748399 — A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the 
European Union (HAI_FY2017) ............................................................................................................................ 19 

DIRECT GRANT WITH INTERNATIONAL ORGANISATIONS ..................................................................... 21 

1. 
20165401  (European  Observatory  on  Health  Systems  and  Policies)  and  20165303  (OECD)  on  the 
State of Health in the EU ........................................................................................................................................ 21 

2. 
20155103  Re-HEALTH:  ‘Support  Member  States  under  particular  migratory  pressure  in  their 
response to health-related challenges’ .................................................................................................................... 22 

3. 
20145401 Ad hoc cooperation with the CoE on specific matters related the improvement of safety and 
quality  of  blood  components  and  tissues  and  cells  for  human  application  and  dissemination  of  best 
practices (Council of Europe/EDQM — DGA) ...................................................................................................... 23 

CALLS FOR TENDERS ........................................................................................................................................ 26 

1. 

20147308 — Study on cross-border health services: potential obstacles for healthcare providers ................ 26 

2.  Services  contract:  20146101  —  Costs  of  unsafe  care  and  cost-effectiveness  of  patient  safety 
programmes report .................................................................................................................................................. 28 

3.  Services contract: 20157305 — BIG DATA in Health report ........................................................................ 29 

1 

 
 
4.  Services contract: 20136101-SHAPING EUROPEAN EARLY DIALOGUES (SEED) report .................... 30 

5.  Services  contract:  20147307  —  Off-label  use  of  medicinal  products  in  the  European  Union  Study 
report ....................................................................................................................................................................... 32 

Background information ......................................................................................................................................... 32 

HIGHLIGHTS OF CO-FUNDED ‘CROSS-CUTTING’ AND ‘OTHER’ ACTIONS .......................................... 33 

1.  Dissemination activities carried out in 2017 ..................................................................................... 33 

2.  Other Actions .................................................................................................................................... 36 

Background information ......................................................................................................................................... 38 

IMPLEMENTATION OF ANNUAL WORK PROGRAMME 2017 .................................................................... 40 

CALLS FOR PROPOSALS ..................................................................................................................... 40 

Project grants .................................................................................................................................................. 42 

European Reference Networks (mono-beneficiary grants) ............................................................................. 42 

Operating grants .............................................................................................................................................. 44 

JOINT ACTIONS ..................................................................................................................................... 47 

DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES ......................................... 50 

PROCUREMENTS (SERVICE CONTRACTS) ...................................................................................... 53 

OTHER ACTIONS ................................................................................................................................... 67 

DETAILED OVERVIEW OF THE REPORTING YEAR 2017 ........................................................................... 71 

Funding per thematic priority and financial instrument ............................................................................ 71 

2 

 
 
 
 
 
Introduction 

This Commission staff working document accompanies the report on the implementation of the third health 

programme 2014-2020 in 2017. While the report provides an overview of all the actions funded under the 

annual work programme for 2017 (2017 AWP) and key co-funded health policy initiatives, including ones 

to implement EU health  legislation, this document showcases  the key results of  actions  co-funded under 

previous financing decisions. 

It  includes  actions  on  overarching  themes  such  as  mental  health,  care  coordination,  European  Reference 

Networks,  cancer,  access  to  care,  health  security  and  patient  safety.  Lastly,  it  provides  comprehensive 

figures and statistics on the health programme’s 2017 operating budget, and lists all co-funded initiatives 

and contracts by programme objective, type of action and type of beneficiary. 

Highlights of initiatives ending in the reporting year — examples of the programme’s results 

Several initiatives co-funded under the second health programme 2008-2013 ended in late 2016 and 2017 

and produced important results that were taken up and built on at national or EU level — some examples 

are  described  in  this  document.  More  information  about  these  and  other  projects  or  joint  actions  can  be 

found  in  the  health  programme  database  managed  by  the  Consumers,  Health,  Agriculture  and  Food 
Executive  Agency  (Chafea)1  (this  database  covers  actions  co-funded  under  the  second  and  third  health 

programmes). 

1 

http://ec.europa.eu/chafea/health/index.html 

3 

 
 
 
 
 
                                                      
JOINT ACTIONS 

Objective 1. Promote health, prevent disease and foster supportive environments for 
healthy lifestyles 

1. 20122202  —  Mental  Health  and  Well-being  (MH-WB)  Joint 

Action 
Background information 

According to the World Health Organization's (WHO) estimates, mental disorders affect 1 in 4 people at 

least  once  in  their  lifetime  and  affect  more  than  10%  of  people  in  the  EU  in  any  given  year. 

Neuropsychiatric  disorders  are  the second leading  cause  of  disability-adjusted life  years  (DALYs)  in  the 

WHO European Region, accounting for 19.5% of all DALYs. 

According to Eurostat, suicide is a significant cause of premature death in the EU, with over 50 000 deaths 

a year, and 9 of the 10 countries with the highest rates of suicide in the world are in the European Region. 

Mental health problems are also associated with productivity losses, with substantial costs to the economy. 

On the other hand, evidence increasingly shows positive mental health and well-being to be a key factor in 

social cohesion, economic progress and sustainable development in the EU. 

Brief description 

The main objective of this joint action was to help promote mental health and well-being, prevent mental 

disorders and improve care and social inclusion for people with mental disorders in Europe. 

National and European working groups evaluated Member State and EU-level progress in this area through 

a 

SWOT 

analysis; 

a 

literature 

review; 

questionnaires 

and 

interviews. 

This  research  and  literature  review,  carried  out  in  collaboration  with  EU  agencies,  the  WHO  and  other 

international organisations led to recommendations for action to improve the effectiveness of mental health 

policies.  

A final conference was organised to endorse Member State and EU recommendations and to underline EU 

commitment for follow-up actions. Close collaboration was established with other European mental health 

initiatives,  and  a  strategy  was  developed  to  create  a  structured  cooperation  in  mental  health  policy  in 

Europe in the future. 

Specific results 

4 

 
 
 
The joint action developed a commonly endorsed framework for action addressing: (a) the  promotion of 

mental  health  in  workplaces  and  schools;  (b)  promoting  action  against  depression  and  suicide;  (c) 

developing  community  mental  health  care;  and  (d)  promoting  the  integration  of  mental  health  in  all 

policies. 

These  outputs  were  further  built  on  by  the  Mental  Health  Compass2  which,  in  parallel,  monitored  the 

mental  health  and  well-being  policies  and  activities  of  EU  countries  and  non-governmental  stakeholders 

and identified European good practices in mental health in the following areas: 

  Preventing depression & promoting resilience 

  Better access to mental health services 

  Mental health at work 

  Mental health in schools 

  Preventing suicide 

  Providing community-based mental health services 

  Developing integrated governance approaches 

The  collected  best  practices  have  been  submitted  to  the  Steering  Group  on  Health  Promotion,  Disease 
Prevention and Management of Non-Communicable Diseases3 for interested Member States to identify the 

ones that they would like to take up and implement in the future. 

The joint action's results are available on the project website4 and in Chafea’s health programme database5. 

Objective 2. Protect EU citizens from serious cross-border health threats 

2. 20122103  —  The  impact  on  maritime  transport  of  health 
threats  due  to  biological,  chemical  &radiological  agents, 
including communicable diseases (SHIPSAN ACT Joint Action) 

Background information 

The EU SHIPSAN ACT joint action brought together competent authorities from 26 countries and industry 

representatives  to  strengthen  and  integrate  sustainable  EU-level  mechanisms  to  protect  the  health  of  sea 

travellers and crewmembers and prevent the cross-border spread of diseases. 

2 
3 
4 
5 

https://ec.europa.eu/health/non_communicable_diseases/mental_health/eu_compass_en 

https://ec.europa.eu/health/non_communicable_diseases/steeringgroup_promotionprevention_en 

http://www.mentalhealthandwellbeing.eu/ 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20122202/summary 

5 

 
 
 
                                                      
Its specific objectives were to: (i) produce a report on the risks and consequences of chemical, biological, 

radio-nuclear (CBRN) events in all types of ships; (ii) improve the quality of inspections; (iii) increase port 

health staff and crew competencies; (iv) develop an outline for a risk assessment tool for occupational and 

public  health;  (v)  develop  guidance  on  health  threats  due  to  chemical/radiological  agents;  and  (vi)  to 

maintain and update SHIPSAN information tools. 

Brief description 

The action focused on the prevention, identification and assessment of CBRN-related cross-border health 

threats and on possible links with existing response mechanisms. 

Methods included literature reviews, surveys and site visits, leading to a comprehensive needs assessment 

exercise.  Focus  groups  and  expert  opinions  were  also  used  in  order  to  reach  a  consensus  among  the 

different categories of stakeholders. 

Dedicated working groups developed preparedness guidelines and training material, and coordinated ship 

inspections were conducted in line with European standards. Information was shared among participating 

countries on routine ship inspections (IHR - ship sanitation certificate (SSC)), ship-associated events and 

response measures using web-based databases. The pool of trainers was updated and a training programme 

involving  face-to-face  learning,  e-learning,  on-the-job  training  and  blended  learning  was  developed  for 

public health officers and the industry. 

Specific results 

The SHIPSAN ACT joint action’s main deliverables include the European manual for hygiene standards 

and  communicable  diseases  surveillance  on  passenger  ships,  the  SHIPSAN  information  system  (SIS), 

training courses, guidelines and risk assessment tools. 

  The  European  manual  (second  edition)6  incorporates  hygiene  standards  based  on  EU  legislation 

and brings together best practice guidelines for passenger ships sailing within European waters. 

  The  SHIPSAN  ACT  web-based  information  system7  contains:  (a)  a  communication  network 

platform for port-to-port and port-to-national authority communication; (b) an information system 

for  recording  and  issuing  ship  sanitation  certificates  under  the  International  Health  Regulations 

2005  for  all  types  of  ships  sailing  in  the  EU  [a  total  of  364  port  health  officers  from  20  EU 

countries  are  registered  to  the  information  system  and  issued  more  than  14 614  ship  sanitation 

certificates (as of  8 June 2018)]; (c)  a database for recording inspections conducted according to 

6 
7 

http://www.shipsan.eu/Home/EuropeanManual.aspx 

EU SHIPSAN ACT information system: https://sis.shipsan.eu/. 

6 

 
 
                                                      
the  European  manual  (303  inspections  from  2011  to  2017);  and  (d)  a  database  for  storing  the 

maritime declarations of health submitted to Member States' 'national single windows'. 

  The joint  action  delivered  e-learning  and  face-to-face8  training  courses  for ship operators,  ships’ 

officers and crew and port health officers. The pool of trainers included 90 subject matter experts 

from  20  countries,  and  a  total  of  1 162  users  signed  up  to  the  e-learning  platform.  The  partners 

gave 11 live webinars with >500 viewers from 21 EU countries and 12 non-EU countries. Training 

courses using the SHIPSAN ACT training materials were organised in Spain, Finland and Norway 

after 2016. In 2018, inspectors from the Netherlands started recording SSC under the International 

Health Regulation (IHR) in the SIS. 

The good practices on preparedness and response developed by SHIPSAN ACT JA and AIRSAN PJ9 have 

been  extended  to  cover  all  three  points  of  entry:  air,  maritime  and  ground  transport,  through  the  new 
HEALTHY GATEWAYS10 joint action funded under the AWP 2017. 

The action's results are available on the project website11 and in Chafea’s health programme database12. 

Objective 3. Contribute to innovative, efficient and sustainable health systems 

3. 20122201  —  Joint  Action  Health  Workforce  Planning  and 

Forecasting (JA EUHWF) 

Background information 

Health workforce issues were put on the EU agenda by the Green Paper on the European Workforce for 

Health  of  the  European  Commission  (2008)  and  the  Commission  Communication  (2010/0682,  final 

23 November  2010).  Member  States  also  requested  that  investing  in  Europe`s  health  workforce  of 

tomorrow be included in the Council Conclusions of 7 December 2010. 

Eighteen countries participated on this joint action, together with international organisations and EU-wide 

health professionals’ organisations. 

Brief description 

8 
9 
10 
11 
12 

EU SHIPSAN ACT e-learning platform: http://elearning.shipsan.eu/. 

http://www.airsan.eu/ 

https://www.healthygateways.eu/, https://webgate.ec.europa.eu/chafea_pdb/health/projects/801493/summary 

EU SHIPSAN ACT website: http://www.shipsan.eu/. 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20122103/summary 

7 

 
 
 
                                                      
The main objective of the joint action on health workforce planning and forecasting (JA EUHWF) was to 

provide  a  collaboration  and  exchange  platform  to  better  prepare  Europe’s  health  workforce  for  future 

challenges and to help countries improve their planning processes. 

The joint action's objectives included: (i) a better understanding of terminology; (ii) better monitoring of 

health workforce issues through access to recent data; (iii) updating information on mobility and migration 

trends in the EU; (iv) guidelines on quantitative and qualitative health workforce planning methodology; 

(v) increasing quantitative and qualitative planning capacity; (vi) estimating future skills and competencies 

needed  in  the  health  workforce;  (vii)  setting  up  a  cooperation  platform  to  find  possible  solutions  to  the 

expected  health  workforce  shortages;  and  (viii)  increasing  the  impact  of  health  workforce  planning  and 

forecasts on policy decision-making. 

The 

joint  action's 

two  main  methods  were  knowledge  sharing  and 

improvement  actions.  

(1)  On  knowledge  sharing,  a  collaboration  platform  was  created  to  enable  dialogue  between  national 

authorities,  experts  and  stakeholders.  The  governance  structure,  procedures  of  communication, 

collaboration,  outputs  and  outcomes  of 

the 

joint  action  were 

included 

in 

this  platform.  

(2) On improvement actions, health workforce data (especially on mobility)  were analysed and assessed. 

The  use  of  pilot  studies,  as  well  as  quantitative  and  qualitative  planning  and  forecasting  tools,  led  to 

improved capacity in several of the participating Member States. 

Specific results 

National  competent  authorities  increased  their  knowledge,  improved  their  tools  and  strengthened  their 

workforce  planning.  The  action's  key  deliverable  —  the  final  Guide  on  health  workforce  planning  and 

forecasting  helped  participating  Member  States  to  reduce  the  gaps  between  the  expected  needs  and  the 

expected supply of health professionals. The national competent authorities also re-designed education and 

training pathways, both in initial and continuous education, to ensure enough healthcare professionals with 

the right skills to meet their needs. 

The action's results are available on the project website13 and in Chafea’s health programme database. 

Objective 4 — Facilitate access to better and safer healthcare for Union citizens 

4. 20112102  — Achieving  Comprehensive  Coordination  in  Organ 

Donation throughout the European Union (ACCORD) 

Background information 

13 

www.euhwforce.eu 

8 

 
 
                                                      
According to the data provided by the Council of Europe's European Committee on organ transplantation 
(CD-P-TO),  more  than  34 024  patients  received  transplants  in  the  EU  in  201714.  However,  this  is  not 

enough  to  meet  patients'  transplantation  needs.  The  Council  of  Europe  data  also  reveal  the  extreme 

disparities in organ transplantation between EU countries. 

The  overall  objective  of  the  ‘Achieving  comprehensive  coordination  in  organ  donation  throughout  the 

European Union’ (ACCORD) joint action was to unleash Member States' full potential in the field of organ 

donation  and  transplantation.  To  achieve  this,  the  action  aimed  to  improve  the  cooperation  between  the 

national competent authorities in line with the requirements of Directive 2010/53/EU ('the Directive') and 

the accompanying action plan on organ donation and transplantation (2009-2015) to strengthen cooperation 

between Member States. 

Brief description 

The joint action had three specific objectives: 

1.  To  improve  Member  States'  information  systems  on  living  organ  donation  by  providing 

recommendations  on  the  design  and  management  of  living  donor  registries  (LDRs)  and  by 

introducing a model for supranational data sharing. 

2.  To  facilitate  the  cooperation  between  critical  care  professionals  and  donor  coordinators,  to 

optimise donation from the deceased. 

3.  To provide practical help to EU countries to share knowledge, expertise and tools specific to the 

Directive and action plan in the form of specific comprehensive exchange protocols (twinnings). 

Specific results 

Training  activities,  exchange  of  best  practices  and  networking  support  in  all  three  fields  have  delivered 

concrete results: 

  Several Member States have already started to create their national LDRs (or modify their existing 

LDRs) taking into account the ACCORD standards and recommendations —  Spain, for example, 

with more than 70 hospitals involved. 

  The joint action's twinning projects have improved access to transplantation, and increased quality 

and safety standards across the EU. 

14 
http://www.ont.es/publicaciones/Documents/NewsleTTER%202018 %20final%20CE.pdf. 

Donation and Transplantation 2017 Newsletter, ONT (ES), 

9 

 
 
                                                      
  Practical  tools  include:  (i)  auditing  and  accreditation  manuals  for  transplant  centres;  (ii)  training 

models  for  auditors;  and  (iii)  e-learning  tools  for  abdominal  organ  procurement  surgeons.  These 

were assessed by the national competent authorities and adapted  as necessary before being rolled 

out. 

  Finally, ACCORD has helped the consistent application of Directive 2010/53/EU and the related 

action plan across the EU through its concrete assistance to Member States. 

The action's results are available on the project website15 and in Chafea’s health programme database16. 

15 
16 

http://www.accord-ja.eu/accord 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20112102/summary 

10 

 
 
                                                      
PROJECTS 

Objective 1. Promote health, prevent disease and foster supportive environments for 
healthy lifestyles 

1. 20121205 — Innovating care for people with multiple chronic 

conditions in Europe (ICARE4EU) 

Background information 

Some 50 million Europeans live with multi-morbidity and their numbers are likely to grow. These people 

have complex health problems and need ongoing care from multiple care professionals and organisations. 

Policymakers  all  over  Europe  are  alarmed  by  the  challenge  this  poses  to their health  systems  and  social 

services. Consequently, many have put multi-morbidity high on their policy agenda. 

The  European  Commission  has  funded  the  ICARE4EU  project  to  help  policy  makers  learn  from  new 

approaches to integrated care, and to share experiences of innovative practices in European countries. 

Brief description 

ICARE4EU analysed current innovative EU approaches to multidisciplinary care for people with multiple 

chronic  conditions.  Expert  organisations  from  30  European  countries  provided  information  on  the 

characteristics of their care programmes for patients with multi-morbidity. 

They  provided  information  on,  for  example:  (i)  the  target  groups;  (ii)  the  disciplines  involved;  (iii)  the 

procedures  and  financing  of  long-term  care;  and  (iv)  the  way  in  which  patients  and  informal  carers  are 

actively  involved.  Country-level  information  on  healthcare  systems  and  their  characteristics  was  also 

collected.  As  a  result,  the  key  characteristics  for  successful  management  and  implementation  strategies 

were identified. 

Specific results 

The ICARE4EU project delivered five policy briefs to help policymakers in European countries adapt their 

health systems to better meet the needs of people with multi-morbidity. 

The  policy  briefs  identify  actions  that  can  improve  the  design  of  integrated  care  for  people  with  multi-

morbidity — including innovative care models and effective implementation — and answer the following 

questions: 

11 

 
 
  How to improve care for people with multi-morbidity in Europe? 

  How to make their care more patient-centred? 

  How to strengthen the related financing mechanisms? 

  How can e-Health improve their care? 

  How to support integration to promote care for people with multi-morbidity? 

The action's results are available on the project website17 and in Chafea’s health programme database18. 

2. Stimulating  Innovation  Management  of  Poly-pharmacy  and 

Adherence in the Elderly (SIMPATHY) 

Background information 

According  to  the  ‘Err  is  Human’  report19,  medication  is  the  most  common  and  the  third  most  costly 

healthcare measure. In addition, up to 11% of all unplanned hospital admissions are attributable to  drug-

related harm. 

The  SIMPATHY  (Stimulating  innovation  management  of  poly-pharmacy  and  adherence  in  the  elderly) 

consortium explored how healthcare management programmes can improve  medicines safety and prevent 

patient  harm.  To  ensure  the  appropriate  use  of  poly-pharmacy  (i.e.  multiple  medications  for  the  same 

patient),  programmes  should  be  developed  in  partnership  with  patients,  as  shared  decision-making  on 

medication improves patient adherence and medicines-related outcomes. 

Brief description 

The  SIMPATHY  initiative  involved  case studies  in a  range  of  healthcare environments,  including  at  the 

reference  sites  of  the  European  Innovation  Partnership  on  active  and  healthy  aging  (EIP-AHA).  This 

provided a framework, and more importantly, baseline data for an EU-wide benchmarking survey of poly-

pharmacy and non-adherence management strategies. 

This  included  innovative  multidisciplinary  models,  using  the  professional  expertise  of  pharmacists  and 

physicians to reduce inappropriate poly-pharmacy and support patients with long-term conditions. A set of 

change-management  approaches  and  tools,  tailored  to  different  situations,  were  also  developed  to  help 

www.icare4eu.org 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121205/summary and 

17 
18 
https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121205/outputs 
19 
Kohn LT, Corrigan JM, Donaldson MS, 'Err is human — building a safer health system'. Washington, 
D.C.National Academy Press; 2000. ISBN: 0-309-068371. https://www.ncbi.nlm.nih.gov/books/NBK225182/ 

12 

 
 
                                                      
policymakers,  regulators,  health  service  providers,  and  other  stakeholders  improve  current  practice  by 

implementing organisational change. 

Specific results 

The  SIMPATHY  case  studies,  benchmarking  survey  and  literature  review  identified  effective  poly-

pharmacy management programmes in the EU, but also underlined that they are too few in number. The 

project also  highlighted that  patients  consider inappropriate  poly-pharmacy  to  be  an  important issue  that 

needs to be addressed. 

The SIMPATHY report calls for EU countries to work together to manage and prevent inappropriate poly-

pharmacy and improve medicines adherence and patient outcomes through a coordinated and collaborative 

change-management approach. 

The consortium delivered five key recommendations: 

1.  Use a systems approach with multidisciplinary clinical and policy leadership. 

2.  Create a culture that encourages and prioritises the safety and quality of prescriptions. 

3.  Empower patients by giving them a central role in medication decisions. 

4.  Use data to drive change.  

5.  Adopt an evidence-based approach. 

Adopting  these  recommendations  will  help  EU  countries  meet  the  WHO  global  challenge  to  improve 

medication safety, of which poly-pharmacy is an essential element. 

The action's results are available on the project website20 and in Chafea’s health programme database21. 

3. 20121211  —  Benchmark  comprehensive  cancer  care  that 
provides  interdisciplinary  treatment  for  patients,  and  yield 
examples  of  best  practice  in  comprehensive  cancer  care 
(BENCH-CAN) 

Background information 

20 
21 

http://www.simpathy.eu/ 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/663082/summary, 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/663082/outputs 

13 

 
 
                                                      
The  number  of  new  cancer  patients  is  steadily  increasing  but  differences  in  EU  health  systems 

performance,  as  attested  by  substantial  differences  in  disease  and  symptom  free  survival  after  primary 

treatment, as well as in prolonged symptom free metastatic disease, show room for improvement.  

By  carrying  out  a  benchmarking  exercise  on  cancer  care  in  Europe,  BENCH-CAN  addressed  the  basic 
principles of the ‘Together for Health’ strategy. It complemented the work of the EPAAC joint action22 on 

healthcare  and  cancer  data  &  information  and  informed  the  Pillar  B  (care  and  cure)  of  the  strategic 
implementation plan of the EIP-AHA23. 

Brief description 

The  general  objective  of  BENCH-CAN  was  to  benchmark  comprehensive  cancer  care  and  yield  best 

practice examples in a way that contributes to improving the quality of interdisciplinary patient treatment. 

To achieve this, the project addressed five action areas: 

1.  Collecting,  comparing  and  aligning  the  standards,  recommendations  and  accreditation  criteria  of 

comprehensive cancer care in selected European countries. 

2.  Reviewing  and  refining  a  benchmarking  tool  that  can  be  applied  to  comprehensive  cancer  care 

through interdisciplinary patient treatment. 

3.  Piloting the benchmark tool with particular attention to operations management and best clinical 

practice. 

4.  Maximising knowledge exchange and sharing of best practice between providers of comprehensive 

cancer care in member states and regions. 

5.  Ensuring compatibility of the benchmarking tools with existing cancer care resources and services. 

The  action  developed  four  benchmarking  tools  using  both  qualitative  and  quantitative  indicators,  and 

piloted them in nine pilot sites. 

Patient  experience  and  satisfaction  were  measured  by  the  European  Cancer  Consumer  Quality  Index. 

Expert  opinion  and  literature  findings  helped  the  BENCH-CAN  partners  identify  good  practices  and 

compare their project with existing or past projects. 

Specific results 

22 

23 

http://www.epaac.eu 

https://ec.europa.eu/eip/ageing/about-the-partnership_en 

14 

 
 
                                                      
  A  quantitative  benchmarking  tool  to  study  the  relative  operational  efficiency  and  resource 

allocation  of  the  participating  centres.  The  framework  comprises  141  indicators  in  seven 

categories:  (i)  medical  activities  per  year;  (ii)  human  resources  input;  (iii)  institution's  capacities 

and  facilities;  (iv)  cost  of  human  resources;  (v)  diagnosis  and  treatment  costs;  (vi)  institution's 

characteristics for comparisons; and (vii) institution's financial information. 

  A  tool  to  measure  patient  experience  and  satisfaction  to  see  whether  care  is  responsive  and 

personalised, which uses the European Cancer Consumer Quality Index questionnaire. 

  A  benchmarking  manual  that  incorporates  the  benchmarking  tools  and  sets  out  the  processes 

necessary for carrying out a self-assessment. 

Although  targeted  to  comprehensive  cancer care  centres, it  can  also  be  used  in general  hospitals 
that provide cancer services and pathways. Above all, it is a publicly available resource24 for all 

interested organisations and parties to use. 

  The  BENCH-CAN  project  also  identified  good  practice  examples  of  clinical  practice,  patient 

experience, and operations management processes at designated comprehensive cancer centres and 

interdisciplinary tumour services. 

The action's results are available on the project website25 and in Chafea’s health programme database26. 

Objective 4. Facilitate access to better and safer healthcare for EU citizens 

4. 20121217  —  NEW  e-HEALTH  SERVICES  FOR  THE 
EUROPEAN  REFERENCE  NETWORK  ON  RARE 
ANAEMIAS (e-ENERCA) 

Background information 

The e-NERCA project focused on designing, validating and implementing information and communication 

technology  (ICT)  tools  to  provide  innovative  and  optimal  care  for  rare  forms  of  anaemia.  e-ENERCA 

centres  involved  health  professionals,  patients,  health  authorities  and  other  national  stakeholders  in  the 

design, validation and implementation of new e-Health services for addressing the challenges posed by rare 

forms of anaemia. 

Brief description 

Project 

BENCH_CAN manual: https://www.oeci.eu/benchcan/Work_Package.aspx. 

24 
25 
http://www.oeci.eu/Benchcan/Rdesources.aspx 
26 
https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121211/outputs 

http://www.oeci.eu/Benchcan/ 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121211/summary, 

website: 

Public 

deliverables:  

15 

 
 
                                                      
The  action  established  the  conditions  for  a  sustainable  European  Reference  Network  (ERN),  which 

include:  (i)  expanding  the  expertise  to  the  whole  EU;  (ii)  collecting  patient’s  data  to  increase  the 

effectiveness  of  epidemiological  surveillance;  (iii)  developing  new  e-health  communication  channels  for 

better  diagnosis  and  treatment;  and  (iv)  establishing  community  reference  e-platforms,  embedded  on 

ENERCA Web, to allow  for easier access of e-learning and  multidisciplinary advice independently from 

the country of practice. 

The  above  were  translated  into  the  action's  five  main  e-health  services:  (i)  data    from  the  ERN's  health 

centres  and  patient’s  associations,  e-registry  and  epidemiological  data;  (ii)  dissemination  of  knowledge 

within  the  ERN  by  updating  existing  information  or  preparation  of  ENERCA  recommendations;  (iii) 

medical  education  through  training  courses  and  e-learning  applications;  (iv)  expert  advice  delivered 

through  ICT  tools,  including  tele-diagnosis  platforms;  and  (v)  empowering  patients  by  improving  links 

with patients’ associations.  

Specific results 

 

e-Registry: an e-Health registry was developed for the epidemiological surveillance of rare  forms 

of anaemia. This provided an inventory of relevant Centres of Expertise with the appropriate skills 

and knowledge to address rare forms of anaemia. It also enabled the pooling of relevant disease-

related data through state-of-the-art standards. 

 

e-Learning  and  training:  e-ENERCA  built  upon  existing  training  tools  and  resources.  Designed 

with  input  from  e-Learning  industry  experts,  it  helped  improve  standards,  which  is  essential  for 

reducing inequalities and variations in the diagnosis, care and treatment of rare forms of anaemia. 

  Telemedicine: The telemedicine platform was developed to enable clinicians and professionals to 

provide  expertise  from  a  distance,  using  virtual  consultation  techniques.  To  develop  the 

telemedicine platform, the project analysed the legal framework of telemedicine services in the EU 

and clarified the legal and ethical considerations of setting up the e-ENERCA platform. 

The action's results are available on the project website27 and in Chafea’s health programme database28. 

https://www.enerca.org/, links to the eENERCA platforms:1. http://www.enerca.org/e-

27 
healthservices/eregistry.html; 2. http://www.enerca.org/e-healthservices/telemedicine.html; 3. 
http://www.enerca.org/e-healthservices/elearning.html 

28 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/20121217/summary 

16 

 
 
 
 
 
                                                      
OPERATING GRANTS 

The 17  non-governmental  organisations  that  signed a  framework  partnership  agreement  (FPA)  in  201729 

were invited to submit their proposal for a specific grant agreement (SGA) under the 2017 AWP to cover 

their operational expenses for that same financial year. 

The FPAs and their SGAs respond to three of the four objectives of third health programme, as follows: 13 

FPA/SGA address objective 1: ‘Promote health, prevent diseases and foster supportive environments for 

healthy  lifestyles  taking  into  account  the  ‘health  in  all  policies’  principle’;  1  addresses  objective  3. 

‘Contribute to innovative, efficient and sustainable health systems’; and 3 address objective 4: ‘Facilitate 

access to better and safer healthcare for Union citizens’. 

Table 1: List of applicant organisations awarded an FPA 2017-2021 and subsequent SGAs 

Acronym 

Organisations 

Thematic 
priority 

CN 

Correlation Network on harm reduction and social inclusion 

AE2018-2021 

Alzheimer Europe 2018-2021 

OBTAINS-E2 
EPHA FPA 2018-2021 

Obesity training and information services for Europe, phase 2 
EPHA multiannual work programme 

AAE 
EUPHA 

THALIA 
EuroHealthNet 

EHN2017 

Stronger together 
Application for an operating grant EUPHA 

Thalassaemia in action 
Strengthening action on health promotion and health equity in the 
EU: EuroHealthNet’s proposal for 2018-2021 
European Heart Network — fighting heart disease and stroke 

SFP FPA 2018-2021 

SFP Coalition’s multiannual work plan 2018-2021 

ENSP FY 2018-2021 

ENSP — the Network — 'United for a tobacco free Europe' 

HAI_FPA2018 

SHE Network 

SAVDON 

ECL FPA 2018-2021 

A plan for action: Ensuring equitable, affordable and responsibly 
used medicines in the EU 

Operating grant 2018-2021 for the SHE network 

High-quality blood stem cells products available for all patients in 
need, and to protect the rights and welfare of volunteer stem cell 
donors 
European Cancer Leagues collaborating for impact in cancer 
control 

TBEC 

FPA 2018-2021 

Strengthening the capacity and capability of civil society to drive 
the TB response in Europe 
Framework partnership agreement 2018-2021 (EURORDIS) 

1.1 

1.1 

1.1 
1.1 
1.1 
1.1 
4.2 
1.1 

1.1 
1.1 
1.1 
3.6 

1.1 
4.5 

1.1 

1.1 

4.2 

29 
them being eligible for financial support on an annual basis for each of the years covered by the FPA. 

In total 17 FPAs were signed with successful  applicant organisations covering 2017-2021, and resulting in 

17 

 
 
 
 
                                                      
Throughout 2017, in line with their SGAs, the organisations achieved their objectives, produced work of 

value  to  their  stakeholders  and  supported  the  Commission's  health  policy  initiatives  in  their  areas  of 

activity. The work and outcomes of two organisations with a 2016 SGA — Alzheimer Europe and Health 

Action International — are presented below: 

1. 742885 — Alzheimer Europe (AE SGA 2017) 

Background information 

Alzheimer Europe is a non-governmental organisation (NGO) comprising 42 member associations from 37 

countries. It aims to provide a voice to people with dementia and their carers, make dementia a European 

priority,  promote  a  rights-based  approach  to  dementia,  support  dementia  research  and  strengthen  the 

European dementia movement. 

Brief description 

The key objectives of Alzheimer Europe’s 2017 operating grant were: 

 

to make an inventory and comparison of care standards for care services for people with dementia 

and their carers and to publish the results in the 2017 'Dementia in Europe' yearbook; 

 

to analyse societal obligations towards people with dementia and develop a rights-based approach 

to dementia together with ethical recommendations; 

 

to  further  develop  the  European  Dementia  Observatory's  monitoring  of  scientific  and  policy 

developments in the field of dementia; 

 

to organise an annual conference in Berlin with the motto ‘Care today, cure tomorrow’ attracting at 

least 500 participants; and 

 

to  support  national  Alzheimer’s  associations  through  the  Alzheimer’s  Association  Academy's 

capacity-building workshops, and provide good governance to the operating grant activities. 

Specific results 

Seventy-three experts from 29 European countries contributed to the 'Dementia in Europe Yearbook 2017: 

Standards for residential care facilities in Europe', providing initial information and feedback on the draft 

report.  The  final  version  of  the  published  report,  approved  by  the  participating  experts,  fed  into  a  peer 

reviewed open access Journal in 2018. 

The  2017  Yearbook  was  distributed  to  over  2 700  stakeholders,  including  all  Members  of  the  European 

Parliament,  key  representatives  of  national  Health  and  Social  Affairs  Ministries,  national  member 

organisations of Alzheimer Europe and other interested stakeholders. Several other key publications were 

produced  during  the  action,  for  example  'Dementia  as  a  disability?  Implications  for  ethics,  policy  and 

practice — a discussion paper'. 

18 

 
 
More  information  about  Alzheimer  Europe  is  available  on  the  organisation’s  website30  and  in  Chafea’s 
health programme database31. 

2. 748399  —  A  Plan  for  Action:  Ensuring  Equitable,  Affordable 
and  Responsibly  Used  Medicines  in  the  European  Union 
(HAI_FY2017) 

Background information 

Health  Action  International  (HAI)  is  a  non-profit,  independent,  global  network  that  aims  to  achieve 

equitable health for all. 

For  Europe,  HAI's  goal  is  to  contribute  to  EU  policy  that  promotes  universal  and  equitable  access  to 

affordable  medicines  for  needed  treatment.  HAI  also  supports  policies  and  practices  that  ensure  that 

medicines  respond  to  societal  challenges,  are  acceptably  safe,  and  appropriately  prescribed  and  used. 

Through its European network, it gives a voice to patients and consumers in decisions that will affect their 

health,  while  advocating  for  high  levels  of transparency,  accountability  and  impartiality  in  all  aspects  of 

EU medicines policy. 

Brief description 

HAI’s work in Europe focuses on three overarching goals:  

1.  Increased access to needed medicines  

2.  Rational use of medicines  

3.  Democratisation of EU medicines policy 

HAI’s  2015-2017  work  plan  was  dedicated  to  identifying,  monitoring  and  supporting  EU  policies  that 

provide  a  response  to  persistent  shortfalls  in  access  to  medicines  and  that  are  aligned  with  HAI’s 

overarching goals. HAI worked towards these goals through research, evidence-based policy analysis and 

intervention, training and information sharing. 

Throughout 2017, HAI made efforts to improve access to essential medicines, their rational use and good 

governance, including  by:  (i) contributing to EU policies that support needs-driven innovation, equitable 

access  to  medicines  in  Europe  and  sustainable  healthcare  systems  through  research-based  advocacy;  (ii) 

advancing  EU  actions on  the  exploration  of  new  models  of  medical  innovation  that  provide solutions to 

30 
31 

https://www.alzheimer-europe.org/ 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/748399/summary 

19 

 
 
 
                                                      
cross-border health threats such as antimicrobial resistance; (iii) raising awareness about the implications 

of pharmaceutical promotion and enabling critical appraisal among (future) healthcare professionals; (iv) 

strengthening health security by supporting marketing authorisation procedures that result in the approval 

of safe and effective medicines; and (v) supporting good governance of medicines policy and contributing 

an independent voice to policy debates. 

Specific results 

HAI  helped  shape  discussions  on  the  need  for  more  transparency  on  medicines  pricing  and  R&D  costs 

supporting civil society's demands. Throughout 2017, HAI advocated for greater transparency of clinical 

trial data and stronger requirements for marketing medicines authorisation and also supported research into 

the evidence of the benefit of oncology drugs approved by the European Medicines Agency. 

HAI was involved in the activities of the Transatlantic Consumer Dialogue and brought together a coalition 

of 25 NGOs from Latin America and Europe that made calls on the need to safeguard access to medicines 

in the EU & Mercosur trade negotiations. 

HAI developed publications on trade and access to medicines, and provided technical expertise to policy 
makers and civil society organisations. 

HAI looked into the main drivers of irrational use of antibiotics, including pharmaceutical promotion, and 
developed a paper with recommendations in this area. 

More information about the work of HAI is available on the organisation’s website32 and in Chafea’s health 

programme database33. 

32 
33 

https://haiweb.org/ 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/748399/summary 

20 

 
 
 
 
 
                                                      
DIRECT GRANT WITH INTERNATIONAL ORGANISATIONS 

1. 20165401  (European  Observatory  on  Health  Systems  and 
Policies) and 20165303 (OECD) on the State of Health in the EU 

Background information 

In 2017, the European Commission completed the first two-year cycle of the State of Health34 in the EU 

initiative and published the first country health profiles. 

Jointly  developed  by  the  Organisation  for  Economic  Cooperation  and  Development  (OECD)  and  the 

European Observatory on Health Systems and Policies, the aim of this work was to build on the ‘Health at 
a  Glance  Europe  201635’  report  to  deliver,  both  an  overarching  (EU-wide)  and  a  country-specific 

understanding of the major challenges facing each EU Member State. 

Following the release of these country health profiles in November 2017, policy dialogues were organised 

with some EU countries on a voluntary basis to help them use the findings and find out more about best 

practices and potential policy responses. 

Brief description 

The  purpose  of  this  initiative  was  to  enable  mutual  learning  and  voluntary  exchange  between  Member 

States to support their evidence-based policymaking. The concise, policy-relevant profiles were based on a 

transparent,  consistent  methodology,  using  both  quantitative  and  qualitative  data,  yet  flexibly  adapted  to 

the context of each EU Member State. 

Each country health profile provides a short overview of: 

  health status 

 

 

 

34  

35 

the determinants of health, focusing on behavioural risk factors 

the organisation of the health system 

the effectiveness, accessibility and resilience of the health system 

https://ec.europa.eu/health/state/summary_en  

https://ec.europa.eu/health/sites/health/files/state/docs/health_glance_2016_rep_en.pdf 

21 

 
 
 
 
                                                      
Specific results. 

The  country  health  profiles  were  accompanied  by  a  companion  report36  with  cross-cutting  conclusions 

from the 28 EU countries. This report highlighted their shared policy objectives, such as: 

 

shifting towards health promotion and disease prevention; 

  a stronger role for primary care; 

  a rethink on fragmented service delivery; 

  proactive planning and forecasting in the health workforce; and 

  better patient-centred data across the EU. 

Once the reports were presented to the national Health Ministries, all EU countries were invited to further 

discuss the findings with OECD and European Observatory on Health Systems and Policies experts. 

These  voluntary  exchanges  took  place  from  the  beginning  of  2018  and  helped  Ministries  to  better 

understand the main challenges and develop the appropriate policy responses. 

More information on the Health at Glance report is available on DG SANTE’s website37. 

2. 20155103  Re-HEALTH: 

‘Support  Member  States  under 
particular  migratory  pressure  in  their  response  to  health-
related challenges’ 

Background information 

The action’s overarching goal was to improve the capacity of EU Member States under particular pressure 

from  migration  (i.e.  Italy,  Greece,  Slovenia  and  Croatia)  to  address  the  health-related  issues  of  arriving 

migrants. This included measures to ensure appropriate surveillance, monitoring, and early warning in case 

of  cross-border  health  threats,  as  well  as  preparedness,  response  planning  and  coordination  of  national 

policies. 

In particular, the project supported these national authorities in their efforts to provide and manage health 

services  at  designated  reception  facilities  for  refugees  and  migrants  during  the  reception  process,  and 

strengthened the coordinated response at national and EU levels. 

36 
37 

https://ec.europa.eu/health/sites/health/files/state/docs/2017_companion_en.pdf 

https://ec.europa.eu/health/state/summary_en 

22 

 
 
 
                                                      
 Brief description 

The action’s specific objectives were to: 

  establish links between key reception areas and the health systems in the target countries; 

  make  use  of  the  established  personal  health  record  (PHR)  and  the  accompanying  Handbook  for 

health professionals to evaluate the health status and needs of arriving refugees and migrants; 

  ensure that health assessments and preventive measures are implemented, taking into account the 

needs of children and other vulnerable groups; and 

  ensure that data initially collected through the PHR is stored in a database so that it is available at 

transit and destination countries. 

 Specific results: 

The development of a database to manage migrant health assessment records that can then be accessed 

at transit and destination countries increased the knowledge on refugees and migrants’ health needs. 

As  a  result,  the  refugees  and  migrants  benefited  from  improved  access  to  health  service  upon  arrival, 

including health prevention, which is especially needed for women and children. This improved access to 

healthcare  also  helped  reduce risks from  undetected diseases  and  therefore to reduce  cross-border  health 

threats. 

Aggregated results from the health assessments show that a substantial number of migrants were victims of 

torture and violence and that an equally high number had significant medical conditions. 

More  than  150  individuals  attended  the  Re-Health  training  courses  on  health  mediation,  on  the  e-PHR 

platform use, and other health-related topics such as gender-based violence and reproductive health. 

More information about Re-Health is available on the International Organisation for Migration’s website38 

3. 20145401 Ad hoc cooperation with the CoE on specific matters 
related  the  improvement  of  safety  and  quality  of  blood 
components  and  tissues  and  cells  for  human  application  and 
dissemination  of  best  practices  (Council  of  Europe/EDQM  — 
DGA)  
Background information 

38 

https://www.re-health.eea.iom.int/re-health  

23 

 
 
                                                      
To increase safety for patients receiving tissues and cells, all professionals involved in the donation cycle’s 

steps must have clear and harmonised technical guidance to ensure the safety and quality of these tissues 

and  cells.  This  includes  those  identifying  potential  donors,  the  transplant  coordinators  managing  the 

process  of  donation  after  death,  the  professionals  working  in  bone  marrow  and  cord  blood  collection 

centres, those in tissue establishments processing and storing tissues and cells, and the inspectors auditing 

any of the establishments and organisations responsible for procedures involving blood, tissues and cells. 

Owing to its mission, expertise, outreach and structure, the Council of Europe can significantly contribute 

to the dissemination of best practices in this area and reach out to different audiences in the EU as well as 

in countries from/to which EU Member States regularly import/export human substances. 

Brief description 

This action involved four main activities: 

1.  A Guide to the quality and safety of tissues and cells for human application (hereinafter, the TC 

Guide).  The  objective  was  to  develop  and  disseminate  common  European  quality  and  safety 

standards for the donation, procurement, testing, processing, preservation, storage and distribution 

of  human  tissues  and  cells,  including  gametes  and  embryos,  which  will  be  published  in  future 

editions of the TC Guide. 

2.  A  blood-proficiency  testing  scheme  (B-PTS)  programme.  The  aim  was  to  organise  proficiency 

testing scheme (PTS) studies for European blood establishments (BE). Participation in PTS studies 

can  provide  testing  laboratories  of  European  BE  with  an  objective  means  of  assessing  and 

demonstrating the reliability of the data they are producing. The B-PTS activity will enable testing 

laboratories of the European BE to maintain and improve their performance. 

3.  A  blood  quality  management  (B-QM)  programme  involving  on-site  training  courses,  visits  and 

audits in BE, as well as training course(s) for quality managers from BE. This programme aimed to 

support BE in implementing/developing their QMS. 

4.  A technical workshop to: (i) collect evidence on the implementation of the EU Directives and the 

CoE guidelines from the experience of the B-PTS, B-QM activities; (ii) develop Blood, Organ and 

TC  Guides;  and  (iii)  formulate  recommendations  to  support  possible  future  EU  regulatory  and 

technical decisions. 

Specific results: 

24 

 
 
The third edition of the TC Guide was published in August 201739. 

Six B-PTS took place40 using the same methodology. 

Each study comprised the following steps: recruitment of the participants, preparation of a study outline, 

performance of a feasibility study if necessary, procurement of material, preparation of samples, invoicing 

and distribution of the samples, protocol to the participants, experimental phase, statistical evaluation, and 

reporting to the participants. 

Each  study  was  followed  up  with  dissemination  and  promotional  activities,  as  well  as  a  comprehensive 

evaluation to review and improve upon the exercise. 

Two  on-site  training/assessment  schemes  were  developed  under  the  B-QM  programme:  (1)  the  B-TVs 

(blood training visits); and (2) the B-MJVs (blood mutual joint visits). Their purpose was to provide BEs 

with tailor-made and effective advice. These visits were performed by peer-experts in European BEs. 

More information about this action is available on the Council of Europe’s website41. 

39 
https://www.edqm.eu/sites/default/files/leaflet-tissues-cells-guide-2017.pdf. The draft of the fourth edition of 
the  Guide  was  finalised  in  November  2018.  It  will  be  ready  for  publication  in  2019  under  grant  agreement 
No 20185301. 
40 
Treponema; B-PTS041 HBsAg/Anti-HBc; B-PTS042 ABO Rha kell & exty and irregular antibodies. 
41 

B-PTS037  HBV/HCV/HIVNAT;  B-PTS038  Anti-HCV;  B-PTS039  Anti-HIV/p24;  B-PTS040  Anti-

https://www.edqm.eu/en/organs-tissues-and-cells-technical-guides 

25 

 
 
 
 
                                                      
CALLS FOR TENDERS 

1.  20147308 — Study on cross-border health services: potential 

obstacles for healthcare providers 

Background information 

Although EU legislation aims to facilitate cross-border health services, in practice, healthcare professionals 

still  face  various  (potential)  obstacles.  These  are  the  result  of  dissimilar  rules  between  Member  States, 

various  (cross-sector)  administrative  requirements,  language  barriers,  and  even  challenges  in  the 

recognition of qualifications process. 

More specifically, this study had the following three objectives: 

1. 

to identify specific and cross-sector national requirements for healthcare  providers, when 

providing cross-border health services; 

2. 

to identify the main barriers to delivering cross-border health services by considering how 

the requirements apply in practice; and 

3. 

to  provide  an  estimate  of  the  amount  of  resources  a  healthcare  provider  would  have  to 

invest in order to meet the various requirements. 

Brief description 

The study investigated five scenarios of cross-border health services provision. 

  Scenario  1:  a  General  Practitioner  (GP)/family  doctor  wishing  to  set  up  a  practice  in  another 

Member States (MS) to offer standard GP services to patients. 

  Scenario 2: A GP wishing to offer online consultations and ePrescriptions to patients (both private 

patients,  and  also  patients  covered  by  or  claiming  reimbursement  from  the  public  healthcare 

system) in one MS while being established in another MS. 

  Scenario  3:  A  physiotherapist  wishing  to  establish  themselves  as  an  independent  practitioner 

offering physiotherapy services in another MS. 

  Scenario  4:  A  medical  services  laboratory  in  one  MS  offering  diagnosis  services  (for  example, 

standard blood sample analysis) in another MS. 

  Scenario 5: A hospital wishing to open a subsidiary branch in another MS. 

Each  of  these  scenarios  were  analysed  for  10  different  MSs:  France,  Germany,  Italy,  Latvia,  Malta,  the 

Netherlands,  Poland,  Slovenia,  Sweden,  and  the  United  Kingdom.  The  analysis  of  the  requirements  that 

cross-border  providers  needed  to  fulfil  in  these  10  EU  countries  provides  a  sound  basis  for  identifying 

26 

 
 
likely  barriers  to  providing  health  services  in  different  types  of  healthcare  systems  and  legislative 

environments within the EU. 

Specific results 

The  study  concluded  that  the  requirements  that  only  apply  to  cross-border  providers  (referred  to  in  the 

study as ‘additional requirements’) mainly concern individual medical professionals. For example: 

 

recognition  of  qualifications  (GPs,  physiotherapists  and  professionals  running  a  medical 

laboratory); 

 

 

language requirements (GPs, physiotherapists and professionals running a medical laboratory); and 

additional  requirements  upon  registration  with  regulatory  bodies  (e.g.  additional  supporting 

documents and certified translations). 

The main obstacles identified were: 

  Language requirements:  all selected Member States have language requirements for cross-border 

GPs, physiotherapists, and professionals running a medical services laboratory. 

  High  costs  associated  with  providing  the  required  supporting  documents  —  and  particularly  the 

certified  translations  of  these  documents  —  in  the  ‘recognition  of  qualifications’  process  and/or 

upon registration with a regulatory body. 

  Registration  with  regulatory  bodies:  the  registration  process  is  crucial,  since  most  regulatory 

bodies  are  in  charge  of  delivering  licences  to  practice.  Although  national  providers  also  need  to 

register  with  the  regulatory  body,  additional  requirements  are  often  imposed  on  cross-border 

providers. 

  Unfamiliarity with the specifics of the healthcare system in a Member State: compared to national 

providers, cross-border providers may experience more practical obstacles in finding the relevant 

information and navigating through the system. This potential obstacle is likely to be even bigger 

in Member States with a decentralised healthcare system. 

More information about the study is available on DG SANTE’s website42. 

42

https://ec.europa.eu/health/sites/health/files/cross_border_care/docs/potentialobstacles_cbhcprovision_frep_e

n.pdf and 

https://ec.europa.eu/health/sites/health/files/cross_border_care/docs/potentialobstacles_cbhcprovision_sum_en.pdf 

27 

 
 
                                                      
 
2. Services contract: 20146101 — Costs of unsafe care and cost-

effectiveness of patient safety programmes report 

Background information 

Given  the  growing  importance  of  patient  safety  for  health  systems,  and  above  all  for  patients,  it  was 

necessary to assess the impact of patient safety measures and to develop priorities for action. The economic 

burden  associated  with  unsafe  patient  care  required  more  action,  particularly  given  the  recent  economic 

crisis. 

The study’s three main objectives were:  

1. 

to provide a comprehensive picture of the financial impact of poor patient safety, including poor 

prevention and control of healthcare-associated infections, on EU health systems;  

2. 

to identify cost-effective patient safety programmes implemented in the EU/EEA Member States 

and analyse their success factors; and 

3. 

 to assess the cost-effectiveness and the efficiency of investment in patient safety programmes. 

Brief description 

A mix of methods was used to answer the research questions. The team conducting the study carried out a 

systematic  literature  search,  as  well  as  desk  research  into  the  evidence  on  the  prevalence  and  costs  of 

adverse  events  and  on  cost-effective  patient  safety  programmes.  It  also  consulted  an  expert  panel  to 

complement  results  from  literature  where  necessary.  Finally,  it  developed  an  econometric  model  to 

calculate the economic burden of adverse events and the cost-effectiveness of patient safety programmes. 

Specific results 

The literature  on  unsafe  care  clearly  demonstrated  the  substantial  burden  of  adverse  events. The  general 

prevalence  of  adverse  events  range  between  4%  and  17%  of  all  patients.  Calculations  based  on  two 

European  references  showed  direct  costs  to  the  public  healthcare  sector  to  be  around  EUR 21  billion  or 

1.5% of Member States’ health expenditure in 2014. 

The literature search on cost-effective patient safety programmes  yielded a  high number of publications. 

These  identified  the  characteristics  of  the  most  promising  interventions  to  be:  (i)  the  use  of  multi-

methodological  approaches;  and  (ii)  the  involvement  of  employees  of  all  professions.  The  origin  of  the 

intervention, i.e. whether it was adapted from existing programmes or developed in-house, had no bearing 

The  study  finally  established  a  basic  econometric  simulation  model  calculating  costs,  effects,  cost-

effectiveness  ratios  and  savings  from  selected  patient  safety  programmes.  The  results  were 

28 

 
 
overwhelmingly positive. Estimated savings (EU-wide) range from EUR 300 million for a programme to 

reduce  several  healthcare-associated  infections,  to  savings  of  about  EUR 2  billion  for  a  programme  to 

reduce pressure ulcers or of around EUR 6 billion for an electronic system to prevent adverse drug events. 

This  report  also  provided  recommendations  on  which  patient  safety  programmes  to  prioritise,  based  on 

identified studies. Such prioritisation must consider a number of key indicators, such as the prevalence of 

the  adverse  event,  the  relevance  of  (easily  preventable)  adverse  events,  and  the  (established)  cost-

effectiveness of the available patient safety practices. 

More information about the study is available on DG SANTE’s website43. 

3. Services contract: 20157305 — BIG DATA in Health report 

Background information 

The European Council called for action on identifying sectoral priorities for research and innovation with 

the greatest potential for social and economic benefits in the data economy. The European Council has also 

emphasised the importance of the digital economy, recognising its high potential as well as the need for a 

strong data value chain in Europe. Both the European Council and Member States (MS) are willing to take 

the  necessary  steps  to  improve  data  innovation,  especially  given  the  exponential  increase  in  data, 

highlighting that making data accessible, assessable, reusable and interoperable is the key to innovation. 

The  purpose  of  the  study  was  therefore  to  explore  how  to  use  big  data  in  health  to  improve  health  and 

health outcomes of people in the EU. The study also aimed to identify practical examples of using big data 

in health and develop recommendations for their implementation. 

Brief description 

The study’s specific objectives were: 

- 

to provide a list of examples of big data in public health, telemedicine and healthcare already being 

used that could be introduced in the EU MS; 

- 

to propose the 10 biggest big data-related priorities for the practice of public health, telemedicine 

and healthcare, where a specific action could be developed, in particular at EU level; 

- 

to develop a list of policy recommendations as a guideline for developing a big data value chain in 

the EU; 

- 

to conduct a SWOT analysis on the feasibility of implementing the proposed policy actions; and 

43 

https://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/2016_costs_psp_en.pdf 

29 

 
 
                                                      
- 

to  organise  an  expert  workshop,  with  all  interested  parties  (national  public  administrations, 

patients/citizens, health professionals, service providers, healthcare payers and industry). 

Specific results 

The suggested recommendations were explicitly from a public health perspective, aiming to improve the 

health of people in the EU as well as the performance of MS’s health systems. They  covered three  four 

broad areas: 

  To  increase  understanding  and  awareness,  the  study  recommended:  (i)  an  overarching 

communication  strategy  to  convince  the public of the  added  value  of  big  data in  health; and  (ii) 

support to health workers to use this data. 

  On  the  data  sets  and  their  analysis,  the  study  recommended:  (i)  facilitating  the  open  use  and 

sharing of big data in health without compromising patients’ rights to privacy and confidentiality; 

(ii)  using  new  and  innovative  analytical  methods;  and  (iii)  developing  standards.    These  factors 

will simplify the application of big data in health and improve interoperability. 

  On  governance  and  financing,  the  study  recommended  appropriate  governance  mechanisms  to 

ensure:  (i)  secure  and  fair  access  to  and  use  of  big  data  for  health  research;  (ii)  the  cost-

effectiveness and sustainability of the funding models; and (iii) clear and well-enforced legal and 

privacy rules for big data in health. 

More information about the service contract is available on DG SANTE’s website44. 

4. Services 

contract: 

20136101-SHAPING  EUROPEAN 

EARLY DIALOGUES (SEED) report 

Background information 

The EU has supported cooperation in the field of health technology assessment (HTA)  for more than 10 
years,  notably  through  the  EUnetHTA  joint  actions45.  Since  November  2013,  the  HTA  network,  set  up 

according to Article 15 of the cross-border healthcare Directive (2011/24/EU) provides strategic guidance 

on voluntary HTA cooperation in Europe. 

In  this  framework,  Chafea  launched  a  call  for  tenders  to  carry  out  ‘early  dialogues’  between  the 

pharmaceutical industry and national HTA bodies that aimed to reduce uncertainty about the needs for data 

generation during the development phase of new health products (pharmaceuticals and medical devices). 

44 
45 

https://ec.europa.eu/health/sites/health/files/ehealth/docs/bigdata_report_en.pdf 

https://www.eunethta.eu/ja3-archive/ 

30 

 
 
                                                      
Brief description 

Under the service contract, the SEED Consortium delivered: 

  methodological protocols and codes of conduct for early dialogues between multiple HTA bodies; 

  11 early dialogues (7 on drugs and 3 on medical devices); and 

 

recommendations for a permanent model for conducting early dialogues. 

To  be a  candidate  for  an  early  dialogue,  companies  had  to  submit  a  letter  of  intent  4  months  before  the 

anticipated date of the start of the procedure. 

Additional templates for the submission file were developed for medicinal products and medical devices, 

including  the  list  of  questions  called  ‘briefing  books’  and  the  ‘key  issues’  to  be  identified  by  SEED 

partners, focusing on the controversial questions on the specific medical technology. 

Specific results 

  Early  dialogues  for  medicinal  products:  on  the  nature  of  the  products,  1  was  an  advanced 

therapeutic  medicinal  product,  6  were  biotherapies,  1  was  a  small  molecule,  3  out  of  8  had  an 

indication in oncology, and 3 were for treating rare diseases. The products were submitted in the 

context of discussions on the design of the Phase III trials. 

  Early dialogues for medical devices: not all requests received met the eligibility criteria, reflecting 

the lack of experience of the medical devices industry on this type of exercise. The three chosen 

products were: (i) 1 implantable medical device developed by a well-established company; (ii) 1 

diagnostic  test  developed  by  a  smaller  company;  and  (iii)  1  medical  device  to  improve  the 

penetration of active products being inserted in parts of the body, developed by a start-up with no 

experience in clinical development. 

The project also provided a series of recommendation on how to strengthen the process of multi-HTA early 

dialogues on issues such as conflicts of interest, involvement of patients, role of regulators and sustainable 

funding models. 

The SEED report is available on the Haute Autorité de Santé — HAS website46. 

46 

http://www.earlydialogues.eu/has/?p=51 

31 

 
 
                                                      
5. Services  contract:  20147307  —  Off-label  use  of  medicinal 

products in the European Union Study report 

Background information 

EU legislation on the marketing authorisation of medicinal products aims to safeguard public health and to 

protect the free movement of these products. As part of this authorisation, the terms under which a product 

can be used safely and effectively are described in the product information. However, medicinal products 

might be prescribed and used outside these terms. This is what is called ‘off-label use’. 

Off-label  use  refers  to  any  intentional  use  of  an  authorised  product  not  covered  by  the  terms  of  its 

marketing  authorisation.  This  may  for  example  be  the  use  for  a  different  indication,  use  of  a  different 

dosage,  dosing  frequency  or  duration  of  use,  use  of  a  different  method  of  administration,  or  use  by  a 

different patient group (e.g. children instead of adults). 

Brief description 

The report’s main aim was to describe existing and planned off-label practices across Member States. Its 

specific objectives were: 

 

 

to provide information on the prevalence and incidence of off-label use, and on its drivers; 

to provide information on the national frameworks (regulatory and other) governing the off-label 

use of medicinal products in various EU countries; and 

 

to  provide  a  factual  analysis  taking  into  account  the  EU  legal  framework  for  off-label  use  and 

practices in the EU countries. 

Applying a wide range of methods, including a systematic review of scientific literature and grey literature 

(i.e. reports and working papers), a legal analysis, interviews with stakeholders and an expert meeting, this 

study  provided  information  on  a  variety  of  aspects  of  off-label  use.  These  include  the  prevalence  and 

incidence of off-label use and its drivers, as well as a description of the national frameworks (regulatory 

and other)  governing the off-label use of medicinal products in the various EU countries. 

A factual analysis was also prepared on how authorities have addressed the issue of off-label use and the 

different ways patients, healthcare professionals and industry react to this. 

Specific results 

32 

 
 
The  reports  investigated  the  balance  between  the  benefits  and  risks  of  off-label use  for  patients,  and the 

regulatory framework for off-label use. 

On the benefits side, off-label use helps to increase patients’ access to (innovative) treatments and to fulfil 

their medical needs, especially when no other option is available. It also contributes to the sustainability of 

the healthcare system.  

Disadvantages include friction between national authorities and the pharmaceutical industry, and important 

liability issues. 

The  report  also  provided  different  policy  options  for  professionals,  industry,  regulators  and  healthcare 

systems,  among  others.  These  included  treatment  guidelines,  how  to  apply  for  permission  to  prescribe, 

appropriate  reimbursement  options,  and  incentives  for  pharmaceutical  companies  to  register  new 

indications. 

The study is available on DG SANTE’s website47. 

HIGHLIGHTS  OF  CO-FUNDED 

‘CROSS-CUTTING’  AND 

‘OTHER’ ACTIONS 

1.  Dissemination activities carried out in 2017 

The dissemination strategy for the third health programme was adopted in June 2017. Its key principle was 

to link up with with activities organised by DG SANTE, international and European organisations, and EU 

countries  in  order  to  promote  the  health  programme  and  disseminate  its  results  at  general  and  thematic 

events.  For  events  organised  by  the  Member  States,  a  close  cooperation  with  the  health  programme’s 

national focal points was essential. 

In 2017, several dissemination activities were organised on key communication priorities indicated by DG 

SANTE, namely refugees’ and migrants’ health, European Reference Networks for rare diseases, the 

fight against antimicrobial resistance, HTA, crisis preparedness in health and chronic diseases. 

47 
label_use_.pdf 

https://ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-

33 

 
 
 
                                                      
In  total  20  dissemination  activities  were  carried  out,  attended  by  more  than  3 000  participants.  These 

included  2  conferences,  11  workshops  and  exhibition  stands  at  high-level  conferences  during  the 

Maltese and Estonian EU Council Presidencies, and two cluster meetings open to journalists. 

Other dissemination actions included: 

 

the  revamping  of  the  online  health  programme  project  database48  to  enable  stakeholders  to 

access projects’ deliverables quickly and easily; 

 

the  production  of  a  set  of  16  third  health  programme  visuals  depicting  the  health  topics  and 

usable on any communication tool; and 

 

the  production  of  online  tutorials  and  videos49  on  six  topics  to  help  potential  applicants  and 

beneficiaries to better prepare and manage their projects. 

In  addition,  Chafea  continued  to raise awareness  on health  programme  funding  opportunities  and  on the 

programme’s results at national, EU-wide and international events. 

  To encourage participation in the health programme by raising awareness on priorities and funding 
opportunities, Chafea organised 2 health programme webinars on 30-31 March 201750, 10 national 
info days 201751, and an info day on 2017 joint actions on 7 June 2017 with 135 participants. 

  To  facilitate  knowledge  sharing  and  disseminate  results,  Chafea  was  present  at  more  than  20 

national and EU-level events. 

  Chafea’s health unit launched the first request for service under DG AGRI’s framework contract 

(lot 2) to organise a series of events, including in particular: 

o  21-22 March  2017,  Madrid,  Spain  —  Workshop  and  stand  on  the  ‘rare  disease 

registries’  —    hosted  by  CIBER  de  Enfermedades  Raras  (CIBERER),  the  Spanish 

network of experts on rare diseases, alongside their annual meeting. Participants: 160. 

o  15 June  2017,  Madrid,  Spain  —  Conference  ‘Preparedness,  Alert  and  Response: 

Lessons  Learned  in  Europe  from  Last  Cross-Border  Health  Infectious  Threats’, 

48 
49 

50 

51 

https://webgate.ec.europa.eu/chafea_pdb/health/projects/ 

http://ec.europa.eu/chafea/health/beneficiaries-corner/project-management/index_en.htm 

130 people participated, raising questions and interacting with SANTE and Chafea. 

The  national  information  days  were  organised  in  Italy,  Sweden,  Ireland,  Greece,  Malta,  Poland,  Slovakia, 

Lithuania, Serbia and Bosnia Herzegovina, with approximately 700 participants. 

34 

 
 
                                                      
organised by DG SANTE and ECDC together with the Spanish Ministry of Health and the 

members of the Health Security Committee. Participants: 125. 

o  08-10 May  2017,  Dublin,  Ireland  —  Workshop  and  stand  during  the  17th 

International  integrated  care  conference  ‘Building  a  platform  for  integrated  care: 

delivering change that matters’. Participants: 211. 

o  8-10 June 2017, Lisbon, Portugal — Conference  ‘Healthy work environment, active 

health  promotion  and  disease  prevention  at  workplace’  organised  by  the  Portuguese 

Health  Directorate  together  with  DG  SANTE,  DG  EMPL,  the  Occupational  Safety  and 

Health Agency and the EU network of workplace health promotion. Participants: 123. 

o  1-4 November  2017,  10th  European Public Health  conference  2017,  Stockholm  (SE) 

—two  workshops  organised  by  Chafea  in  collaboration  with  DG  SANTE,  the  European 

Observatory on Health Systems and Policies, European Implementation Collaborative, the 

Centre for Implementation Science, CLAHRC South London and King’s College London 

and the EUPHA Section on Public Health Policy and Practice. The two workshops focused 

on:  ‘Sharing  health  information  and  evidence  with  policy  makers:  tools  for  transferring 

knowledge into policy action’ and ‘Implementation of innovations in public health policy 

and practice’. Participants: more than 100. 

35 

 
 
2.  Other Actions 

Collaboration with DG GROW in the field of medical devices development and maintenance, 
in support to the new Regulations on medical devices and in-vitro diagnostic medical devices 
by the legislators. 

  Communication campaign 

This communication and information campaign aimed to inform stakeholders about the legislative 
changes introduced by the new Regulations on medical devices52 and in-vitro diagnostic medical 
devices53. The campaign targeted all stakeholders — particularly manufacturers — to ensure that 

they were aware of the requirements and timelines of the new Regulations. It therefore also aimed 

to avoid any disruptions to the medical devices market following the legislative modifications.   
Tools included a new online hub dedicated to the new regulations on DG GROW’s54 website. This 

hub provides information to the main stakeholders  affected by the legislative change, namely: (i) 

manufacturers  of  medical  devices  and  in-vitro  diagnostic  medical  devices;  (ii)  authorised 

representatives, importers and distributers; (iii) health institutions reprocessing single-use medical 

devices;  (iv)  manufacturers  of  devices  without  an  intended  medical  purpose;  (v)  healthcare 

professionals; (vi) health institutions; and (vii) institutions in charge of the procurement of medical 

devices and in-vitro diagnostic medical devices. The hub also targets authorities in non-EU/EEA 

countries that make use of the EU approvals system. 

The campaign produced six factsheets and translated them into EU languages as well as non-EU 

languages such as Chinese, Japanese and Arabic. The campaign also involved webinars targeted at 

stakeholders and other easy-to-understand information material. 

DG  GROW  liaised  with  competent  national  authorities  to  design  and  disseminate  the  campaign 

material at national level. 

  European medical devices database (Eudamed) 

A key way of meeting the objectives of the two new Regulations on medical devices and in-vitro 
diagnostic medical devices was to create a European database on medical devices (Eudamed)55. 

52            Regulation EU 2017/745. 
53 
54  

Regulation EU 2017/746. 

The Commission’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs 

55 

https://ec.europa.eu/growth/sectors/medical-devices/new-regulations/eudamed_en 

36 

 
 
 
 
                                                      
The database integrates different electronic systems to collate and process information on devices 

on  the  market,  including  information  on  the  manufacturers,  certain  aspects  of  conformity 

assessment, notified bodies, certificates, clinical investigations, vigilance and market surveillance. 

The  database  also  aimed  to  increase  transparency,  for  example  by  giving  the  public  and  health 

professionals  better  access  to  information.  Other  objectives  included:  (i)  avoiding  multiple 

reporting requirements; (ii) improving coordination between Member States; and (iii) streamlining 

and  facilitating  the  flow  of  information  between  manufacturers,  notified  bodies  or  sponsors,  and 

Member  States  —  as  well  as  among  Member  States,  and  between  Member  States  and  the 

Commission.  As  within the  internal  market  this  can  only  be  ensured effectively  at  EU  level,  the 

Commission was tasked with further developing and managing the existing European databank on 
medical devices (Eudamed2) set up by Commission Decision 2010/227/EU56. 

In  2017,  the  maintenance  and  support  of  the  existing  Eudamed2  continued,  in  parallel  with  the 

feasibility analysis for the creation of an entirely new and separate Eudamed, in line with the new 

Regulations’ requirements. 

  Scientific and technical support from Joint Research Centre (JRC) 

The Administrative Arrangement (AA) between DG GROW and the JRC ran from August 2015 to 

April 2017. It aimed to help set up scientific bodies — scientific panels for medical devices and 

European  Reference  Laboratories  (EURLs)  for  in-vitro  diagnostic  medical  devices  —  together 

with  some  elements  on  medical  devices  nomenclature.  For  the  scientific  panels  JRC  provided 

support on surveys — including the relevant implementing acts for their design and fees, and a call 

for  experts.  For  EURLs,  JRC  provided  implementing  acts  on  tasks  and  compliance,  developed 

principles for conflict of interest, and organised a call for applications by laboratories. Finally, on 

nomenclature JRC provided support at international (IMDRF) and EU level. 

  Joint assessments of notified bodies 

The  action  covers  the  expenses  of  national  experts  who  participate  in  the  joint  assessments  of 

notified  bodies  together  with  the  Commission’s  services  in  line  with  Article 3  of  Commission 

Implementing  Regulation  (EU)  No 920/2013  and  Articles  38-42  and  123(3)(a)  of  Regulation 

2017/745 on medical devices and Articles 34-38 and 113(3)(b) of Regulation 2017/746 on in-vitro 

diagnostic medical devices. 

56 
(Eudamed) (OJ L 102, 23.4.2010, p. 45). 

Commission  Decision  2010/227/EU  of  19 April  2010  on  the  European  Databank  on  Medical  Devices 

37 

 
 
 
 
                                                      
  Meetings of Medical Device Coordination Group (MDCG) 

The  funding  covers  the  organisation  and  reimbursement  of  expenses  for  the  meetings  of  the 

MDCG and its subgroups. The group’s tasks are laid down in the Regulations on medical devices 

and in-vitro diagnostic medical devices. 

The budget for all activities under Priority 3.6 related to the new medical devices Regulations was 

EUR 4 637 189,27, broken down as follows: 

o  EUR 520 000,00 for the information and communication campaign;  

o  EUR 2 218 000,00 for the development of the future Eudamed following the adoption of 

new medical devices Regulations;  

o  EUR 1 350 000,00 for the AA with JRC; and  

o  EUR 549 189,27 in support to the MDCG for meetings on the new Regulations.    

Development and maintenance of the European Health Care Quality on cancer (JRC) 

Background information 

The  European  Commission’s  science  and  knowledge  service,  the  Joint  Research  Centre  (JRC),  supports 

EU policies with independent scientific evidence throughout the whole policy cycle.  The JRC’s work on 

health  care  quality  on  cancer  involves  the  coordination  and  operational  management  of  the  European 
Commission’s  initiative  on  breast  cancer  (ECIBC)57,  which  aims  to  ensure  the  quality  of  breast  cancer 

services across European countries. 

An  important  part  of  the  ECIBC  is  quality  assurance  for  breast  cancer  services.  For  this,  the  JRC 

coordinates  the  Quality  Assurance  Scheme  Development  Group  (QASDG),  which  has  developed  a 

European QA scheme, applicable to breast cancer services in the EU. 

The QASDG has defined six main processes of breast cancer care that the European Breast QA scheme 

should cover: (i) screening; (ii) diagnosis; (iii) treatment; (iv) rehabilitation; (v) follow-up and survivorship 

care;  and  (vi)  palliative  care;  and  four  quality  areas:  (i)  clinical  effectiveness;  (ii)  safety;  (iii)  personal 

empowerment and experience; and (iv) facilities, resources and workforce. 

Brief description 

The  ECIBC  included  a  Guidelines’  platform  —  a  publicly  accessible  collection  of  evidence-based 

guidelines for breast cancer. The platform covers selected topics of the patient care pathway and therefore 

57 

https://ecibc.jrc.ec.europa.eu/ 

38 

 
 
                                                      
complements  the  ECIBC  screening  and  diagnosis  recommendations.  It  also  includes  a  collection  of 

trustworthy evidence-based guidelines for breast cancer services. 

Specific results 

The ECIBC web hub is a ‘one-stop shop’ for breast cancer patients, professionals and policy makers. Is is 

a user-friendly platform for health stakeholders and the public to exchange messages. It should become a 

key  resource  for  stakeholders,  especially  women  looking  for  information  on  where  to  go  and  how  to 

receive care compliant with the most up-to-date European standards. 

The  Guidelines  platform  hosts  existing  high-quality  guidelines,  developed  by  expert  bodies  outside  the 
European Commission. The  platform covers all breast cancer care processes after diagnosis58 (treatment, 

rehabilitation, survivorship, palliative care). 

The JRC has also developed a targeted European training template for digital breast cancer screening 

(the ECIBC training template). The training template aims to decrease disparities in skills and services 

and,  in  turn,  will  eventually  considerably  improve  the  quality  of  care.  The  ECIBC  training  template’s  

minimum requirement is to define the essential training programmes healthcare professionals must follow 

in order to be able to perform screening services that comply with the European Breast Quality Assurance 

Scheme. It focuses on the skills a professional must possess to be able to adequately perform the assigned 

tasks.  The  skill-focused  structure  of  the  template  will  allow  its  application  in  different  countries,  by 

different professionals and within a diverse array of legal frameworks. 

The  budget  for  all  activities  under  Priorities  1.4  and  1.5.4.  was  EUR 2 300 000,00,  broken  down  as 

follows: 

o  EUR 2 200 000,00  for:  (i)  the  development  and  maintenance  of  the  healthcare,  quality, 

health  data  information  (HQHDI)  for  rare  diseases registries and the  cancer registry; (ii) 

the  update  of  the  EU  guideline  on  breast  and  colorectal  cancer  screening,  including  the 

European  quality  assurance  scheme;  and  (iii)  data  compilation  for  chronic  diseases, 

particularly  on  nutrition  and  physical  activity,  and  related  publications,  including 

summaries of scientific studies  

o  EUR 100 000,00  for  laboratory  support  for  the  revised  Tobacco  Products  Directive’s 

(2014/40/EU) requirement on the submission of extensive data by industry (see Articles 5 

and 6 (tobacco) and 20 (e-cigarettes)).  

58 

http://ecibc.jrc.ec.europa.eu/guidelines-methodology 

39 

 
 
 
                                                      
IMPLEMENTATION OF ANNUAL WORK PROGRAMME 2017 

CALLS FOR PROPOSALS 
Calls  for  proposals,  including  one  for  projects,  and  an  invitation  to  apply  for  the  European  Reference 

Networks  specific  grants and  operating  grants for  civil society  organisation (SGA),  were  all  launched in 
March 201759 on the Horizon 2020 programme’s Participant Portal, on the Europa public health website60 
and on Chafea’s website61. 

For the call for proposals for projects (supporting Member States in mainstreaming health promotion and 

disease prevention in health and educational settings), 11 proposals were submitted, but as none of them 

reached the quality threshold, no projects were funded. 

All applications for ERNs specific grants for 2017 and 94% of FPA/SGA applications for operating grants 
were submitted by organisations in EU-1562 Member States, the only exception being an SGA signed with 

an EU umbrella organisation from Cyprus. 

Of the 6 joint actions signed, 5 (83%) proposals were from organisations in EU-15 Member States, and the 

remaining joint action (iPAAC)  was coordinated by Slovenia. Of the 217 joint action beneficiaries, 51% 

were represented by organisation from EU-15 countries, 33% by organisations from countries that joined 
the EU after 200463, 14% by non-EU countries participating in the health programme (Bosnia Herzegovina 
(BH), Republic Serbia (RS) and Moldova), and 2% by EEA64 countries (Norway). 

59 
health and educational settings, PJ-01-2017 on17 March 2017 and FPA on 28 March 2017. 

Project  call  on  supporting  Member  States  in  mainstreaming  health  promotion  and  disease  prevention  in 

60 
61 

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/pj-01-2017 
http://ec.europa.eu/chafea/health/archives/news/news493.html 

62 
EU-15 countries (Belgium (BE), Denmark (DK), France (FR), Germany (DE), Greece (EL), Ireland (IE), 
Italy (IT), Luxembourg (LU), Netherlands (NL), Portugal (PT), Spain (ES), United Kingdom (UK), Austria (AT), 
Finland (FI), and Sweden (SE)). https://ec.europa.eu/eurostat/statistics-
explained/index.php/Glossary:EU_enlargements 

63 
EU  countries  that  joined  the  EU  after  2004:  Cyprus  (CY),  Czechia  (CZ),  Estonia  (EE),  Hungary  (HU), 
Latvia (LV), Lithuania (LT), Malta (MT), Poland (PL), Slovakia (SK), Slovenia (SI), Bulgaria (BG), Romania (RO) 
and Croatia (HR). 

64 
EEA countries participating in the health programme (Norway (NO) and Iceland (IC)). 
https://ec.europa.eu/eurostat/statistics-explained/index.php/Glossary:European_Economic_Area_(EEA) 

40 

 
 
                                                      
Chafea  organised  a  workshop  for  joint  actions  on  7 June  2017  and  a  joint  action  quality  assurance 
workshop  on  18-20 October  2017.  The  health  programme’s  national  focal  points65  also  organised  nine 

national information days (hosted in IT, PL, SE, IR, EL, RS, SK, LT, and BH) between March and June 

2017. Guidelines for applicants were made available on the Participant Portal. The Chafea helpdesk also 

provided assistance and practical help. 

Altogether, 23 proposals for ERNs and 16 operating grant proposals were received with a  total proposed 

budget of EUR 10 316 224,31. However the total available budget for that year for the call for proposals — 

including for projects — and for ERNs and SGAs, was EUR 9 850 000,00. 

Applications  were  evaluated  in  accordance  with  the  rules  and  criteria  set  out  in  2017  AWP66  and  the 

specific  calls  for  proposals.  There  was  also  an  external  evaluation  of  the  call  for  proposals  to  ensure  an 

efficient and transparent selection of AWP 2017 proposals. 

The proposals submitted under the various calls were evaluated by external experts (peer-reviewers). Nine 

external  experts  from  7  countries  (AT,  BE,  EL,  ES,  IT,  RO  and  SE)  evaluated  the  FPA/SGA  and  ERN 

proposals, and 12 experts from 9 countries (DE, EL, ES, IT, LT, MT, NL, RO and NO) ensured the quality 

assurance of the 2017 joint actions. The experts were drawn from the list that was established following the 
call for expressions of interest in the area of public health — the EMI H2020 database67. 

65 

http://ec.europa.eu/chafea/health/national-focal-points/index_en.htm 

66 
Commission Implementing Decision of 26.1.2017 C(2017) 316 final. 
https://ec.europa.eu/health/sites/health/files/programme/docs/wp2017_en.pdf 

67 

EMI. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert 

41 

 
 
 
                                                      
 
 
The evaluation process took place in two stages: 

In  the  first  stage,  three  external  evaluators  reviewed  each  proposal,  and  then  a  consolidated  evaluation 

report for each proposal was drawn up at a consensus meeting organised by Chafea. 

In the second stage, the evaluation committee checked that the evaluators had complied with the relevant 

rules and criteria. It then drew up final lists of proposals recommended for funding, together with reserve 

lists.  The  evaluation  committee  comprised  representatives  from  the  Directorate-General  for  Health  and 

Food Safety (DG SANTE), the Directorate-General for Research and Innovation (DG RTD), and Chafea. 

The  award  decisions  for  16  operating  grants  were  taken  by  Chafea.  Under  the  third  health  programme, 

there is no award decision for projects and ERNs, as it is signed together with the grant. 

Project grants 

Project grants were awarded to actions involving several partners, usually public health bodies and NGOs. 

The maximum EU contribution is 60% of eligible costs. However, the EU contribution may go up to 80% 

if a proposal meets the criteria for exceptional utility. In total, 11 proposals were submitted to the call for 

proposals for projects. Ten proposals were evaluated and 1 was rejected. No single proposal reached the 

threshold  values.  Therefore,  no  projects  were  funded  in  2017  and  the  budget  was  re-allocated  to  other 

financial mechanisms. 

European Reference Networks (mono-beneficiary grants) 

ERNs,  together  with  their  proposals  to  become  an  approved  ERN,  which  was  conditional  on  their 

assessment by the Independent Assessment Bodies and ensuing decision of the Board of Member States, 

had also submitted  an FPA proposal, together with their SGA proposals for their first year of operation. 

Once the decision of the Board of  Member States was taken and the 23  ERNs approved, Chafea invited 

them to the grant agreement preparation phase, with a view to sign the related FPAs and SGAs as quickly 

as possible in the year N+1. 

According  to  the  financing  decision,  each  ERN  could  receive  up  to  EUR 200 000,00.  However,  not  all 

ERNs requested the full available amount. The co-funding awarded to them is in the table below. 

Financial instrument 

Objective: 

Chafea ERN actions SGAs under FPA by 
objective 
4 

42 

 
 
 
 
                                                                                                                                                                             
 
 
Description of 
objective: 

4. Facilitate access to better and safer 
healthcare for EU citizens 

Thematic priority: 

4.1 Support the establishment of a system of 
European reference networks for patients with 
conditions requiring highly specialised care … 

User reference 

Title 

811290- ERN-RND — 
ERN-SGA-2017 
811463 — ERN-
PAEDCAN Y2 — 
ERN-SGA-2017 
811269 — ERKNet — 
ERN-SGA-2017 
811239 — ERN-NMD 
— Y2- ERN-SGA-
2017 
811440- ERN 
GENTURIS — ERN-
SGA-2017 
811324 — ERN-SKIN 
-2 ERN-SGA-2017 

811403- ERN 
GUARD HEART — 
ERN-SGA-2017 
811633 — ERN-
RECONNET — 
ERN-SGA-2017 
811490- EURACAN 
2- ERN-SGA-2017 
811570 — Endo-ERN 
— ERN-SGA-2017 
811609 — VASCERN 
— ERN-SGA-2017 
814736 — ERN-
LUNG — ERN-SGA-
2017 
811442 — ERN 
BOND — ERN-SGA-
2017 
811487 — ERN-
ITHACA — ERN-
SGA-2017 
811585 — MetabERN 
— ERN-SGA-2017 

European Reference Network for Rare 
Neurological Diseases 
Paediatric Cancer European Reference 
Network Y2 

European Rare Kidney Diseases Reference 
Network 
Rare Neuromuscular Disease European 
Reference Network 

European Reference Network on Genetic 
Tumour Risk Syndromes — GENTURIS 

European Reference Network for Rare, Low 
Prevalence, Diagnosed and Undiagnosed Skin 
Disorders — Year 2 
Gateway to Uncommon And Rare Diseases of 
the Heart 

ERN Rare Connective Tissue And 
Musculoskeletal Diseases Network 

ERN Rare Adult Cancers 

ERN Rare Endocrine Conditions 

Amount 
committed 

200 000,00 

200 000,00 

200 000,00 

199 183,00 

192 072,92 

200 000,00 

178 636,50 

199 999,00 

199 983,00 

200 000,00 

ERN Rare Multi-systemic Vascular Diseases 

199 986,85 

ERN Rare Respiratory Diseases 

199 422,00 

European Reference Network on Bone rare 
Diseases 

200 000,00 

ERN Rare Congenital Malformations And Rare 
Intellectual Disability 

140 998,00 

ERN Rare Hereditary Metabolic Diseases 

200 000,00 

43 

 
 
 
 
The European Reference Network in Rare 
Liver Disease 

European Reference Network for rare and 
complex epilepsies 
European Reference Network on Rare 
Immunodeficiency, Autoinflammatory and 
Autoimmune Diseases: Year 2WP 
ERN Rare Eye Diseases 

198 955,80 

195 425,02 

199 964,38 

199 904,03 

ERN Rare Haematological Diseases 

199 781,41 

ERN Rare Craniofacial Anomalies and ENT 
Disorders 
ERN Inherited And Congenital Anomalies 

ERN Transplantation In Children 

200 000,00 

200 000,00 

200 000,00 

4 504 311,91 

811422- ERN-RARE-
LIVER — ERN-SGA-
2017 
811547 — EpiCARE 
— ERN-SGA-2017 
8111246- ERN RITA 
— Y2- ERN-SGA-
2017 
811427- ERN-EYE — 
ERN-SGA-2017 
811641 — ERN-
EuroBloodNet — 
ERN-SGA-2017 
811672 — CRANIO 
— ERN-SGA-2017 
811632 — ERNICA 
— ERN-SGA-2017 
811558- ERN 
TRANSPLANTChild 
— 2nd Y, ERN-SGA-
2017 
Chafea TOTAL ERN 
SGAs 

Operating grants 

Operating  grants  may  be  awarded  to  non-governmental  bodies  that  pursue  one  or  more  of  the  health 

programme’s specific objectives. Operating grants were awarded to non-profit organisations that are: 

  non-governmental; 

  non-profit-making and independent of industry, commercial and business or other conflicting 

interests; 

  working in the public health area; 

  playing an effective role in civil dialogue processes at EU level; 

  pursuing at least one of the programme’s specific objectives; 

 

active at EU level and in at least half of the Member States; and 

  balanced in terms of EU geographical coverage. 

All activities included in Annex 1 of the Regulation establishing the third health programme can be funded 

by a specific grant awarded under a framework partnership agreement (FPA). 

FPA recipients are eligible for a specific grant agreement (SGA) (operating grant). These FPA recipients 

were invited to submit an application for an SGA to cover their operating costs for 2018.  The maximum 

EU contribution is 60% of their annual operating costs. However, the EU contribution may increase to 80% 

44 

 
 
  
 
if  a  proposal  meets  the  criteria  for  exceptional  utility.  In  2017,  from  the  16  operating  grants  signed,  6 
(38%)68 qualified for exceptional utility. 

In  2017,  a  call  for  proposals  was  organised  for  the  signature  of  four-year  FPAs  for  2018-2021,  in 

particular,  but  not  limited  to,  the  following  priority  areas:  prevention  and  health  determinants;  chronic 

diseases;  cancer;  dementia;  rare  diseases;  HIV/AIDS,  tuberculosis,  hepatitis;  access  to  healthcare;  and 

substances of human origin. 

Out  of  the  17  applicants  granted  an  FPA,  only  16  received  an  SGA.  This  is  because  one  applicant 

organisation — EuroHealthNet — had to withdraw their proposal because they received a grant from DG 

EMPL covering their costs for 2018. EuroHealthNet’s proposal was therefore removed  from the ranking 

list. 

By  the  end  of  2017,  the  grant  preparation  process  had  been  completed  representing  a  budget  of 

EUR 5 811 912,40 

The following table lists all operating grants funded by objective and priority. 

Financial 
instrument 
Objective: 
Description of 
objective: 

Thematic priority: 

User reference 

824194 — 
OBTAINS-E2 — 
SGA-01-2017 
811123- EUPHA 
SGA-2017 — 
SGA-01-2017 
81125 — SFP 
SGA 2018 — 

Chafea operating grants by 
objective 
1 
1. Promote health, prevent diseases 
and foster supportive environments for 
healthy lifestyles taking into account 
the ‘health in all policies’ principle 

1.1 Cost-effective promotion and 
prevention measures in line, in 
particular, with the EU strategies on 
alcohol and nutrition … 
Title 

Obesity Training and Information 
Services in Europe phase 2 

European Public Health Association 
(EUPHA) 2018 

Preventing cancer and chronic 
diseases through smoking prevention 

Amount committed 

226 410,00 

292 714,00 

419 906,40 

68 
Operating grants, SGA 2017 with EC funding higher than 60% were granted to the Smoke Free Partnership, 
Correlation  Network,  AIDS  Action  Europe,  European  Network  for  Smoking  and  Tobacco  Prevention,  European 
Public Health Alliance and Thalassaemia in Action. 

45 

 
 
 
 
 
 
                                                      
SGA-01-2017 

811127 -EHN 
SGA 2018-SGA-
01-2017 
824213 — ENSP 
FY 2018 — SGA-
01-2017 
824205 — EPHA 
2018 — SGA-01-
2017 
811128 — 
SHE2018 — SGA-
01-2017 
Total 
Thematic priority: 

User reference 
811114- TBEC — 
SGA-01-2017 
811116 — AAE — 
SGA-01-2017 
811124-CN- SGA-
01-2017 
Total 
Thematic 
priority: 

User reference 
809963 — AE2018 
— SGA-01-2017 
811112 — ECL 
SGA 2018 — 
SGA-01-2017 
Total 
Objective: 
Description of 
objective: 
Thematic priority: 

User reference 
811117 — 
HAI2018 — SGA-

— 2018 annual work plan for the 
Smoke Free Partnership 
European Heart Network — 
Cardiovascular Health at the Heart of 
EU Policies 
European Network for Smoking and 
Tobacco Prevention — Paving the 
way for a tobacco free Europe 
European Public Health Alliance 
(EPHA SGA 2018) 

SCHOOLS FOR HEALTH IN 
EUROPE FOUNDATION 

1.3 Support effective responses to 
communicable diseases such as 
HIV/AIDS, tuberculosis and 
hepatitis … 
Title 
TBEC: strengthening TB response in 
the WHO Europe region 
AIDS Action Europe — Stronger 
Together 
Correlation — European Harm 
Reduction Network 

1.4 Support cooperation and 
networking in the Union in relation 
to preventing and improving the 
response to chronic diseases … 
Title 
Alzheimer Europe 

European Cancer Leagues -
Collaborating for Impact in Cancer 
Control (2018) 

3 
3. Contribute to innovative, efficient 
and sustainable health systems. 
3.6 Implementation of EU legislation 
in the field of medical devices, 
medicinal products and cross-border 
healthcare 
Title 
A Plan for Action: Ensuring 
Equitable, Affordable and 

46 

370 861,00 

393 648,00 

584 206,40 

248 847,00 

2 536 592,80  

Amount committed 

124 210,00 

280 492,00 

214 713,60 

 619 415,60 

Amount committed 

472 785,00 

302 895,00 

775 680,00 

Amount committed 

250 000,00 

 
 
  
 
  
 
  
 
 
 
Responsibly Used Medicines in the 
European Union 

4 
4. Facilitate access to better and safer 
healthcare for EU citizens 
4.2 Coordinated action at EU level in 
order to effectively help patients 
affected by rare diseases 
Title 
Eurordis Rare Diseases Europe SGA 
2018 

250 000,00 

Amount committed 

1 027 785,00 

THALassaemia In Action 2018 

297 828,00 

4.5 Implementation of EU legislation 
in the fields of human tissues and 
cells, blood, human organs, medical 
devices, medicinal products, and 
patients’ rights in cross-border health 
care 
Title 
Equal access to high-quality cells for 
transplants for donors whose rights 
and safety are protected. 

1 325 613,00  

Amount committed 

304 611,00 

304 611,00 
5 811 912,40 

01-2017 

Total 
Objective: 
Description of 
objective: 
Thematic priority: 

User reference 
811115 — 
EURORDIS SGA 
2018 — SGA-01-
2017 
824224 — 
THALIA SGA 
2018 — SGA-01-
2017 
Total 
Thematic priority: 

User reference 
811126 — 
SAVDON — 
SGA-01-2017 
Total 
Chafea TOTAL 
OPERATING 
GRANTS 

JOINT ACTIONS 

The  grants  for  actions  co-financed  with  Member  State  authorities  are,  according  to  Article.7  2(a)  of  the 

third health programme 2014-2020 Regulation, ‘actions having a clear Union added value co-financed by 

the  competent  authorities  of  Member  States  responsible  for  Health  or  by  public  sector  bodies  and  non-

governmental  organisations,  acting  individually  or  as  a  network,  mandated  by  these  competent 

authorities.’ 

They therefore allow the nominated national authorities of the Member State/other countries participating 

in the programme and the European Commission to work together on jointly identified issues. 

47 

 
 
 
 
 
 
 
  
 
  
  
 
 
Grants  for  joint  actions  were  awarded  to  competent  authorities  or  public  sector  bodies  and  non-

governmental bodies mandated by those competent authorities. 

The  maximum  EU  contribution  is  60%.  However,  the  EU  contribution  may  go  up  to  80%  if  a  proposal 

meets  the  criteria  for  exceptional  utility.  Four  (67%)  out  of  the  6  joint  actions  2017  qualified  for 
exceptional utility69. 

The  procedure  for  joint  actions  changed  under  the  third  health  programme  to  increase  transparency  and 

inclusiveness.  Member  States  and  other  countries  participating  in  the  third  health  programme  now 

nominate  the  competent  authorities  or  other  bodies  as  a  first  step.  As  a  second  step,  their  nominees  are 

invited to submit a proposal under the direct grant procedure. 

Six  joint  actions  were  co-funded  for  a  total  budget  of  EUR 20 229 410,14,  covering  the  following 

objectives: 

  health promotion (2 joint actions); 

  health threats (2 joint actions); and 

  health systems ( 2 joint actions). 

There were no joint actions for the ‘better and safer healthcare’ objective. 

Each of the six joint actions involved between 20 and 49 beneficiaries from EU/EEA countries and other 

countries participating in the programme. 

The table below lists all the joint actions funded per objective and priority. 

Financial 
instrument 
Objective: 
Description of 
objective: 

Thematic priority: 

Chafea Joint actions by objective 

1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 
taking into account the ‘health in all policies’ 
principle 

1.1 Cost-effective promotion and prevention 
measures in line, in particular, with the EU 
strategies on alcohol and nutrition … 

69 
The four joint actions that qualified for exception utility in 2017 are the joint actions on health inequalities, 
on health  information, on the  Innovative Partnership on  Action against  Cancer,   and  on preparedness and action at 
points of entry. 

48 

 
 
 
 
 
 
                                                      
User reference 

Title 

Amount committed 

 801600 — HP-JA-
2017 

Total 
Thematic priority: 

User reference 
 801520 - HP-JA-
2017 

Total 
Objective: 
Description of 
objective: 
Thematic priority: 

User reference 
801493- HP-JA-
2017 
801495- HP-JA-
2017 
Total 
Objective: 
Description of 
objective: 
Thematic priority: 
User reference 
801558- HP-JA-
2017 
Total 
Thematic priority: 

User reference 
801553- HP-JA-
2017 
Total 
Chafea TOTAL 
JOINT ACTIONS 

 Joint Action Health Equity Europe (JAHEE) 

2 499 997,02  

1.4 Support cooperation and networking in the 
EU in relation to preventing and improving the 
response to chronic diseases … 
Title 
 Innovative Partnership for Action Against 
Cancer (iPAAC) 

2 
2. Protect EU citizens from serious cross-border 
health threats 
2.2 Capacity-building against health threats in 
Member States, including, where appropriate, 
cooperation with neighbouring countries 
Title 
Preparedness and action at points of entry 
(Healthy Gateways) 
European Joint Action on Vaccination (EU-JAV) 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 
3.2 Innovation and e-health 
Title 
 Joint Action supporting the e-Health Network 
(eHAction) 

3.7 Health information and knowledge system 
including support to the Scientific Committees 
set up in accordance with Commission Decision 
C(2015) 5383 
Title 
Information for Action (InfAct) 

2 499 997,02  

Amount committed 

4 500 000,00  

4 500 000,00  

Amount committed 
3 000 000,00 

3 530 231,97 

6 530 231,97 

Amount committed 
2 699 989,67 

2 699 989,67 

3 999 191,48 

3 999 191,48 
20 229 410,14 

49 

 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES 

Direct grant agreements with international organisations were awarded to international organisations active 

in  the  area  of  public  health.  The  direct  grants  also  include  service-level  agreements.  The  maximum  EU 

contribution is 60%. 

All in all, 8 direct grant agreements were signed by Chafea for a total of EUR 9 300 000,00, as follows: 

1)  2 direct grants (EUR 2 200 000,00) signed with the WHO for: (i) the State of Health in the EU 

country knowledge; and (ii) support for the implementation of national action plans on 

antimicrobial resistance (AMR). 

2)  4 direct grants (EUR 2 800 000,00) signed with OECD for: (i) the EU health report ‘State of 

Health in the EU’; (ii) the development of patient-reported measures; (iii) challenges to access to 

medicines; and (iv) trends and policies affecting the international migration of doctors and nurses. 

3)   1 direct grant (EUR 3 300 000,00) signed with the Council of Europe on European Pharmacopoeia 

(European Directorate for the Quality of Medicines and Healthcare (EDQM)) (CoE — EDQM). 

4)  1 direct grant (EUR 1 000 000,00) signed with the International Organisation for Migration (IOM) 

for the implementation of the Personal Health Record as a tool for integration of refugees in EU 

health systems (RE-HEALTH 2). 

The table below lists all direct grant agreements that were funded per objective and priority. 

Financial 
instrument 
Objective: 
Description of 
objective: 

Thematic priority: 

User reference 

20175101 (IOM) 

Total 

Thematic priority: 

Chafea direct grant agreements by objective 

1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 
taking into account the ‘health in all policies’ 
principle 
1.1 Risk factors such as use of tobacco and passive 
smoking, harmful use of alcohol, unhealthy dietary 
habits and physical inactivity 
Title 

Implementation of the Personal Health Record as a 
tool for integration of refugees in EU health 
systems (RE-HEALTH 2) 

1.6 Health information and knowledge system to 
contribute to evidence-based decision-making 

50 

Amount committed 

1 000 000,00 

1 000 000,00 

 
 
 
 
 
 
 
 
 
User reference 

Title 

Amount committed 

20175102(WHO)  

State of Health in the EU cycle  

20175103 (OECD) 

State of Health in the EU cycle  

Total 
Objective: 
Description of 
objective: 
Thematic priority: 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 
3.4. Provide expertise and share good practices to 
assist Member States undertaking health system 
reforms … 
Title 

User reference 
20175303 (OECD)  Challenges for access to medicines 
Total 
Thematic priority: 

3.6 Implementation of EU legislation in the field of 
medical devices, medicinal products and cross-
border health care 
Title 
European Pharmacopoeia (EDQM) 

User reference 
 20175301(Council 
of Europe) 
Total 
Thematic priority: 

3.7. Foster a health information and knowledge 
system to contribute to evidence-based decision-
making 
Title 

User reference 
20175302 (OECD)   Develop patient-reported measures 
20175304(OECD)   Trends and policies affecting the international 

migration of doctors and nurses 

4 
Facilitate access to better and safer healthcare 
for EU citizens 
4.4  Measures  to  prevent  antimicrobial  resistance 
and control healthcare-associated infections 
Title 
Support to implementation of national action plans 
on AMR 

Total 
Objective: 
Description of 
objective: 
Thematic priority: 

User reference 
20175401 (WHO) 

Total 
Chafea TOTAL 
DIRECT 
GRANTS 

Presidency conferences 

51 

1 600 000,00 

1 500 000,00 

3 100 000,00 

Amount committed 
600 000,00 
600 000,00 

Amount committed 
3 300 000,00 

 3 300 000,00 

Amount committed 
500 000,00 
200 000,00 

700 000,00 

Amount committed 
600 000,00 

600 000,00 
9 300 000,00 

 
 
  
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
  
 
 
The  Presidency  conferences  financed  under  the  2017  AWP  included  one  on  tackling  the  harmful  use  of 
alcohol, under the Estonian Presidency70, and one on pharmaceutical products and one on healthy nutrition 
— both under the Bulgarian Presidency. 

1.  The conference ‘Cross-Border Aspects in Alcohol Policy — Tackling Harmful Use of Alcohol’ 

aimed to reduce alcohol-related harm in the EU by strengthening the Member States’ capacities to 

implement effective health policy and tackle cross-border issues. The conference was held together 

with  a  debate  at  the  Informal  Meeting  of  Health  Ministers  on  30 October  2017  in  Tallinn.  Both 

events fed into the Council conclusions on these issues. 

2.  Under the Bulgarian EU Council Presidency71 two conferences were organised. 

•  The  first  on  ‘Healthy  Future  for  Europe:  A  Healthy  Child  Nutrition’  took  place  on 

6 February  2018.  Discussions  and  debates  by  EU  and  international  experts  focused  on 

subjects such as healthy food and food for children, the link between nutrition and health, 

the  impact  of  food  on  children’s  development,  healthy  eating  habits  as  a  key  health 

determinant, food marketing regulation practices for children, the role of traditional diets, 

and prospects for a ‘healthier’ future common agricultural policy responsive to the needs 

of affordable, healthy food. 

•  The conference on Options to provide better medicines for all European citizens took 

place on 6 March 2018. It aimed to provide a platform for discussion on key issues related 

to drug deficiency, legal possibilities and e-solutions to regulate parallel exports as well as 

securing effective medicines at affordable prices. 

70 

71 

https://www.eu2017.ee/political-meetings/cross-border-aspects-alcohol-policy-tackling-harmful-use-alcohol 

https://eu2018bg.bg/en/news/news 

52 

 
 
 
 
 
                                                      
Financial 
instrument 
Objective: 
Description of 
objective: 

Thematic priority: 

Health programme support to Presidency 
conferences by objective 
1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles taking 
into account the ‘health in all policies’ principle 
1.1 Cost-effective promotion and prevention 
measures in line, in particular, with theEU strategies 
on alcohol and nutrition … 

User reference 

Title 

785803 EE-PCY  

Estonian Presidency conference on Cross-Border 
Aspects in Alcohol Policy — Tackling Harmful Use 

Bulgarian Presidency Conferences on Drug Shortages 
and on Healthy Nutrition for Children 

807392 DSHNCH 

Chafea TOTAL 
PRESIDENCY 
CONFERENCES 

Amount 
committed 
148 620,00 

61 439,00 

210 059,00 

PROCUREMENTS (SERVICE CONTRACTS) 

Procurement  (service  contracts)  was  used  to  purchase  services.  Contrary  to  the  grants,  the  health 

programme  covers  the  full  cost  of  the  procurement  action.  These  services  were  implemented  through 

service contracts based on existing framework contracts, services contracts or new framework contracts to 

cover needs as specified in the work plan for 2017. They include: 

 

 

evaluation, monitoring of actions and policies, including impact assessment; 

studies, data analysis and information on health; 

  databases development and maintenance; 

  organisation of workshops, training, expert panels and coordination groups; 

 

 

 

 

scientific and technical assistance, provision of advice and opinions; 

communication, translations and publications; 

awareness raising and dissemination of the results; and 

information technology applications in support of policies. 

In  2017,  DG  SANTE  signed  several  service  contracts  and  specific  requests  using  existing  framework 

contracts  (FWC).  Most  of  these  contracts  and  requests  were  for  cross-cutting  actions,  such  as 

communication and IT services for the maintenance and functioning of existing IT tools. 

53 

 
 
 
 
 
 
 
  
 
 
 
 
Procurement  contracts  also  included  contracts  with  experts  working  for  the  scientific  committees,  and 

evaluation  and  monitoring  studies.  The  overall  public  procurement  budget  implemented  by  DG  SANTE 

under AWP 2017 was EUR 8 717 409,07. 

The overall public procurement budget implemented by Chafea under AWP 2017 was EUR 5 863 073,68. 

In 2017, CHAFEA managed 29 new market procedures for the acquisition of services (8 contracts under 

health  promotion,  3  contracts  under  health  threats,  3  contracts  under  health  systems,  1  under  better  and 

safer health care) and 14 (48%) for measures to support the dissemination of health programme results. 

The amounts per objective and authorising organisation were as follows: 

Health programme 

Procurement 

Procurement 

objective 

managed by DG 

managed by Chafea 

SANTE 

 (EUR) 

(EUR) 

1. Health promotion 

881 500,00 

3 515 257,00 

2. Health threats 

0 

668 318,00 

3.Health systems 

3 257 945,25 

633 035,70 

4. Better and safer 

1 553 490,00 

272 541,75 

healthcare systems 

5. Horizontal actions 

3 024 473,82 

773 921,23 

TOTAL 

8 717 409,07 

5 863 073,68 

The  table  below  lists  all  service  contracts  signed  per  objective  and  per  priority  by  Chafea  and  by  DG 

SANTE. 

Financial instrument 
Objective: 
Description of objective: 

Thematic priority: 

Chafea Calls for tender by objective 
1 
1. Promote health, prevent diseases and 
foster supportive environments for healthy 
lifestyles taking into account the ‘health in 
all policies’ principle 
1.1 Cost-effective promotion and prevention 
measures in line, in particular, with the EU 
strategies on alcohol and nutrition … 

54 

 
 
 
 
 
 
 
 
User reference 

Title 

20177107 -
CHAFEA/2017/HEALTH/31 
20177113 — 
CHAFEA/2017/HEALTH/01 
20177110- 
CHAFEA/2017/HEALTH/07 

20177111 -
CHAFEA/2017/HEALTH/08 
Total 

Thematic priority: 

User reference 

20177124-
CHAFEA/2017/HEALTH/32 

Total 
Thematic priority: 

User reference 

20178507 — SC 
2017/HEALTH/34 UNDER 
FWC CHAFEA/2015/CP/01 

20177129 –RFS CHAFEA 
2017 Health 36 under FWC 
CHAFEA/2016/HEALTH/36  

20177128 -RFS CHAFEA 
2017 Health 35 -UNDER 
FWC CHAFEA/2016/ 
HEALTH/36 
Total 
Objective: 
Description of objective: 

Thematic priority: 

Pilot on food reformulation support and 
monitoring 
EU dimension of alcohol-related harm

European expert network — Rare 
communicable diseases and other rare 
pathologies linked to globalisation/ 
migration 
Analyses of collected information — health 
status of refugees 

1.3 Support effective responses to 
communicable diseases such as HIV/AIDS, 
tuberculosis and hepatitis … 
Title 

Support for Member States in 
mainstreaming health promotion and 
disease prevention including lifestyle 
medicine in health and educational settings 

1.5 Actions required by, or contributing to, 
the implementation of EU legislation in the 
field of tobacco products … 
Title 

Provision of behavioural studies — second 
wave study about consumer preference and 
perception of specific categories of tobacco 
and related products  
Tobacco technical group: organise, 
coordinate and manage the administrative 
system and coordination of the entire 
technical group 
Maintenance of the group of sensory 
assessors, including performance 
monitoring 

2  
2. Protect EU citizens from serious cross-
border health threats 
2.2 Capacity-building against health threats 
in Member States, including, where 

55 

Amount 
committed 
1 399 939,00 

999 397,00 

184 278,00 

148 395,00 

2 732 009,00 

Amount 
committed 
248 910,00 

248 910,00 

Amount 
committed 
288 338,00 

131 000,00 

115 000,00 

534 338,00 

 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
User reference 

20177202 — RFS 
CHAFEA/2017 HEALTH/18 
UNDER FWC CHAFEA/ 
2015/ HEALTH/05 LOT 1  
20177205 — RFS 
CHAFEA/2017/HEALTH/26 
UNDER FWC CHAFEA/ 
2015/HEALTH/05 LOT 1  
20177206 -RFS 
CHAFEA/2017/HEALTH/27 
UNDER FWC CHAFEA/ 
2015/HEALTH/05 LOT 3 
Total 

Objective: 
Description of objective: 

Thematic priority: 

User reference 

201710206 — SC 
IMPLEMENTING 
CHAFEA/2017/AGRI/06 
LOT 2 
20177123 

Total 
Thematic priority: 

User reference 

20177304 RFS 
CHAFEA/2017/HEALTH729 
IMPL FWC PO_2016-12_A2 
Total 
Objective: 
Description of objective: 

Thematic priority: 
User reference 

appropriate, cooperation with neighbouring 
countries 
Title 

Inter-sectoral table top exercise on hybrid 
threats towards improving preparedness and 
strengthening capacity to coordinate 
response 
Inter-sectoral table top exercise on business 
continuity planning during a pandemic

Organising a training on entry and exit 
screening 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 
3.1 Support voluntary cooperation between 
Member States on health technology 
assessment … 
Title 

Stakeholders forum on EU cooperation on 
HTA 

Amount 
committed 
229 209,00 

229 209,00 

209 900,00 

668 318,00 

Amount 
committed 
105 035,70 

Purchase order for expert HTA conference

8 000,00 

3.6 Implementation of EU legislation in the 
field of medical devices, medicinal products 
and cross-border health care 
Title 

Information and communication campaign 
on the new Regulations on medical devices

4 
4. Facilitate access to better and safer 
healthcare for EU citizens 
4.1 European Reference Networks  
Title 

113 035,70 

Amount 
committed 
520 000,00 

520 000,00 

Amount 
committed 

56 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
20177401 RFS CHAFEA/ 
2017/HEALTH/19 IMPL 
FWC/2015/HEALTH/09 

European Reference Networks (ERN) — 
Assessment of healthcare providers — Join 
ERN by Independent Assessment Bodies

272 541,75 

272 541,75 

Total 
Objective: 
Description of objective: 

Thematic priority: 
User reference 

201717103 -CHAFEA/2017/ 
HEALTH/22 under 
Framework Contract n° 
SANCO/2012/04/09 Lot 2 
201710201 SC 
IMPLEMENTING 
CHAFEA/2017/AGRI/06 
LOT 2 
20177121 

20177118 

20177120 

20177122 

20177127 

20177115 

20177114 

20177116 

20176101 

5 
5. IT / dissemination (Horizontal action 
related to all objectives)  
horizontal IT / dissemination 
Title 

Amount 
committed 

Organisation of two cluster meetings 

186 518,43 

Organisation of five (5) events, with the 
exhibition of the health programme pop-up 
stand.   

PURCHASE ORDER -AIDS 2018, 
AMSTERDAM Rent a space for three 
satellite symposia and three shell scheme 
packages 
PURCHASE ORDER INT CONF ON 
INTEGRATED CARE UTRECHT 
(ICIC18)  
PURCHASE ORDER IHR CONFERENCE 
ATHENS JUNE 18 — PURCHASE 
ORDER 
PURCHASE ORDER INHSU 
PORTUGAL, 19-21 SEPTEMBER 2018

EUROPEAN 

PURCHASE ORDER  
HEALTH FORUM GASTEIN 2018 
STAND FEE   
PURCHASE ORDER  
CONFERENCE NOV 17 STOCKHOLM 
— venue expenses, exhibition space rental, 
registration fees and catering services

EUPHA 

AMEX FOR 

PURCHASE ORDER  
EUPHA CONFERENCE NOV 17 
STOCKHOLM 
PURCHASE ORDER UNIVERSITY OF 
PATRAS organisation of a workshop on 
national policies and EU best practice for 
tackling antimicrobial resistance 
PURCHASE ORDER Exhibition space 

57 

394 331,70 

71 460,00 

10 800,00 

3 600,00 

5 000,00 

7 000,00 

14 750,00 

17 677,95 

10 000,00 

600,00 

 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20177101 

20177102  

20177126  

Total 
Chafea TOTAL CALLS 
FOR TENDER 

Financial instrument 
Objective: 
Description of objective: 

Thematic priority: 

rental for the exhibition of Chafea Health 
Unit stand at the XVIII Congreso Nacional 
Sobre el Sida e ITS from 22-24 March 
2017, Seville, Spain.   
PURCHASE ORDER Conference Health At 
Work, 8-9 June 2017, Lisbon, Portugal. 
PURCHASE ORDER International 
conference on integrated care (ICIC) 8-
10 May 2017 Dublin, Ireland  
RFS CHAFEA/ 2017/ HEALTH/28 -
Quality Consultant 

SANTE Calls for tender by objective 
1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 
taking into account the ‘health in all policies’ 
principle 
1.1 Cost-effective promotion and prevention 
measures in line, in particular, with the EU 
strategies on alcohol and nutrition … 

User reference 

Title 

SANTE/2017/C4/040 

C4 - 17030100 — SC 32  

Study on exposure of children to linear, non- 
linear and online marketing of foods high in 
fat, salt and sugar 
JR PROJECT MANAGER AND JR ONLINE 
COMMUNITY MANAGER EU HEALTH 
POLICY FORUM AND EU HEALTH 
AWARD  

Total 

Thematic priority: 

1.5 Actions required by, or contributing to, 
the implementation of EU legislation in the 
field of tobacco products … 

User reference 

Title 

7678 D1/ISS/SP 

STUDY ON MEASURING THE ILLICIT 
MARKET IN TOBACCO PRODUCTS  

DIR B — 17.030100 — 
SI2.763974  
Total 
Objective: 

PROJECTS UNDER THE HEALTH 
PROGRAMME 2017  

3 

58 

3 000,00 

7 500,00 

41 683,15 

773 921,23 
5 863 073,68 

Amount 
committed 
500 000,00 

186 500,00 

686 500,00 

Amount 
committed 
150 000,00 

45 000,00 

195 000,00 

 
 
 
  
  
 
 
 
 
 
  
 
 
 
 
  
 
Description of objective: 

Thematic priority: 

User reference 

SANTE/2017/02/020  

Total 
Thematic priority: 

3. Contribute to innovative, efficient and 
sustainable health systems 
3.4 Setting up a mechanism for pooling 
expertise at EU level  
Title 

Workshops/hearings of Expert Panel on 
effective ways of investing in health  

3.6 Implementation of EU legislation in the 
field of medical devices, medicinal products 
and cross-border healthcare 

User reference 

Title 

Medical Device Coordination Group 
(MDCG) — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

Amount 
committed 

39 945,25 

39 945,25 

Amount 
committed 

18 000,00 

GROW/D4/2017 — 
MDCG MEETINGS IN 
2017 (COVERING 
TRAVEL EXPENSES OF 
PARTICIPANTS) 
GROW.R.3 — CS 9631 
— DI/7330 -E-ORDER 
2017-10929 -
APPLICATION 
ARCHITECT / 
DESIGNER (AAD) 
GROW.R.3 — CS 9630 
— CC DI/7330 — E-
ORDER 2017-11184 
GROW.R.3 — CS 10063 
— DI/7335 — E-ORDER 
2017-15552-0 — 
PROJECT MANAGER / 
LEVEL 3  
GROW.R.3 -CS 10079 — 
DI/7331 — E-ORDER 
2017-15798-0 — 
DATABASE 
DEVELOPER / LEVEL 5 
— EUDAMED  
GROW.R.3 — CS 10100 
— CC DI/7330 -E-
ORDER 2017-16533-0 — 
DATABASE 
DEVELOPER LEVEL 4 
— EUDAMED  
GROW.R.3 — CS 10096 
— CC DI/7335 — E-
ORDER 16766-0 - 
BUSINESS ANALYST 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

10 826,62 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

79 604,80 

20 476,80 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

52 015,78 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

16 438,58 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

60 721,20 

59 

 
 
 
 
 
 
  
 
 
 
 
 
LEVEL 5 — EUDAMED  

GROW.R.3 — CS 9057 — 
CC DI/7337 — E-ORDER 
2017-17789-0 — 
ENTREPRISE 
ARCHITECT LEVEL 4 
— EUDAMED  
GROW.R.3 — CS 10225 
— CC DI/7333 — E-
ORDER 2017-18489-0 — 
APPLICATION 
ARCHITECT/DESIGNER 
LEVEL 1 
GROW.R.3 — CS 10712 
— CC DI/7331 -E-
ORDER 2017-21733-0 — 
APPLICATION 
ARCHITECT/DESIGNER 
LEVEL 3 
GROW.R.3 — CS 10711 
— CC DI/7335 — E-
ORDER 2017-21755-0 — 
INTERFACE DESIGNER 
LEVEL 3 
GROW.R.3 — CS 10595 
— CC DI/7335 — E-
ORDER 2017-23469 
ENTREPRISE 
ARCHITECT LEVEL 4 
GROW.R.3 — CS 1587 — 
CC DI/7390 — E-ORDER 
2017-24724 — 
WORKSTATION 
ADMINISTR. LEVEL5 
GROW.R.3 — CS 11010 
— CC DI/7331 — E-
ORDER 2017-25915 - 
APPLICATION 
ARCHITECT/DESIGNER 
LEVEL 3 — EUDAMED  
GROW.R.3 — CS 11015 
— CC DI/7330 — E-
ORDER 2017-27652 — 
DATABASE 
DEVELOPER LEVEL 1 
— MEDICAL DEVICES 
PROJECTS  

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

167 754,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

34 408,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

129 288,00 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

122 672,00 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

74 187,38 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

12 302,42 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

77 572,80 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

62 802,00 

60 

 
 
GROW.R.3 — CS 11013 
— CC DI/7335 -E-
ORDER 2017-28870-0 — 
BUSINESS ANALYST 
LEVEL 3 
GROW.R.3 — CS 11014 
— CC DI/7335 — E-
ORDER 2017-28871 — 
BUSINESS ANALYST 
LEVEL 3 
GROW.R.3 — CS 11187 
— CC DI/7335 — E-
ORDER 2017-28880 — 
BUSINESS ANALYST 
LEVEL 5 
GROW.R.3 — 
SLG.CMM.2017.33145 — 
CS 001681 — CC 
DI/07390 — E-ORDER 
2017-33145-0 — 
SYSTEM ADMINISTR. 
LEVEL 4  
GROW.R.3 — CS 11745 
— CC DI/7331 — E-
ORDER 2017-35249-0 — 
APPLICATION 
ARCHITECT/DESIGNER 
LEVEL 4 — PTM  
GROW.R.3 — CS 11768 
— CC DI/7335 — E-
ORDER 2017-37208-0 — 
ENTERPRISE 
ARCHITECT LEVEL 2 
GROW/R3 — 
SLG.CMM.2017.39513 — 
CS 012156 — CC DI/7338 
— E-ORDER 2017-39513 
— IS SUPPORT 
MANAGER 
GROW R3 — CS 9056 — 
CC DI/7334 — E-ORDER 
2017-45099 — 
APPLICATION 
ARCHITECT/DESIGNER  
GROW.R.3 — CS 12299 
— CC DI/7331 — E-
ORDER 2017-45291 — 
DATABASE 
DEVELOPER LEVEL 5 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

87 878,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

87 878,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

119 622,60 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

17 922,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

85 327,20 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

12 606,22 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

31 013,84 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

177 094,00 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

45 980,80 

61 

 
 
GROW.R.3 — CS 12842 
— CC DI/7330 — E-
ORDER 2017-45463-0 
APPLICATION 
ARCHITECT/DESIGNER  
GROW.R.3 — CS 12349 
— CC DI/7331 — E-
ORDER 2017-46649-0 — 
APPLICATION 
ARCHITECT/DESIGNER  
GROW.R.3 — CS 12960 
— CC DI/7331 -E-
ORDER 2017-46708-0 — 
APPLICATION 
ARCHITECT/DESIGNER  
GROW.R.3 - CS 12811 — 
CC DI/7330 - E-ORDER 
2017-47160-0 QUALITY 
CONSULTANT (QC) 
GROW.R.3 — CS 12862 
— CC0 DI/7333 — E-
ORDER 2017-48080 
APPLICATION 
ARCHITECT/DESIGNER  
GROW/R3 — GLOBAL 
COMMITMENT FOR IT 
SPECIFIC CONTRACTS  

 DIR B — 17.030100 — 
SI2.763974 - 
 DIR B — 17.030100 — 
SI2.763974 - 
Total 

Thematic priority: 

User reference 

C2 — ONLINE WRITER 
AND WEB/VISUAL 
DESIGNER 
C2 - 17030100 — 
REIMBURSEMENT OF 
EXPERT COSTS AND 
INDEMNITIES FOR 
C2 - 17030100 — 
REIMBURSEMENT OF 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

21 053,60 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

10 842,40 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators  

11 926,60 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators —  

66 039,60 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

70 795,20 

MDCG — meetings on new regulations and 
in-vitro diagnostic devices by legislators 

432 947,56 

PROJECTS UNDER THE HEALTH 
PROGRAMME 2017 
PROJECTS UNDER THE HEALTH 
PROGRAMME 2017 

3.7 Health information and knowledge system 
including support to the Scientific 
Committees set up in accordance with 
Commission Decision C(2015) 5383 
Title 

ASSISTANCE TO SCIENTIFIC 
COMMITTEES AND HEALTH EU 
NEWSLETTER  
SCIENTIFIC COMMITTEES — DEG 

100 000,00 

300 000,00 

2 618 000,00 

Amount 
committed 
250 000,00 

347 000,00 

SCIENTIFIC COMMITTEES — DEG 

3 000,00 

62 

 
 
 
  
 
 
EXPERT COSTS AND 
INDEMNITIES FOR 
Total 
Objective: 
Description of objective: 

Thematic priority: 
User reference 

B3 - 17030100 — 
SANTE/2017/B3/046 - 
B3 - 17030100 — 
CATERING  
B3 - 17030100 — 
SANTE/2017/B3/071  
DIR B — 17.030100 — 
SI2.763974  
Total 
Objective: 
Description of objective: 

Thematic priority: 
User reference 

4 
4. Facilitate access to better and safer 
healthcare for EU citizens 
4.1 European Reference Networks 
Title 

ORGANISATION 4TH CONFERENCE ON 
ERN — 21-22/11/2018 — BRUSSELS  
CONFERENCE ON ERN — 21-22/11/2018 
— BRUSSELS  
DUBBING AND SUBTITLING OF ERN 
VIDEO CLIP — 87 SECONDS 
PROJECTS UNDER THE HEALTH 
PROGRAMME 2017  

5 
5. IT / dissemination (Horizontal action 
related to all objectives)  
horizontal IT / dissemination 
Title 

C4 — SI2.760871 - 

EU HEALTH AWARD — PRIZES 

C4 — SI2.760871 - 

EU HEALTH AWARD — DEG —   

B3 - 17030100 — 
SANTE/2017/B3/015  
B3 - 17030100 — 
SANTE/2017/B3/016 - 
CO-DEL DG SANTE - 

SC 490 - 
SC 528 GC - 
SC 526 - 
02 — SC 524 
02 — SC 525 - 
02 — SC 527- 
02 — SC 60 - 
SC 9 - 

SC 14- 
SC 15 - 
SC 24 - 
02 — 

PRODUCTION OF ERN BROCHURE IN 
NORWEGIAN —  
EXPRESS SHIPMENT OF ERN 
MATERIAL - 
TRANSLATIONS 2017 UNIT 02 + DIR B & 
C  
WEB MAINTENANCE — DEG 
WEB DEVELOPER 
JB — SENIOR WEB CONSULTANT 
AS — SENIOR ONLINE WRITER 
SR — SENIOR ONLINE WRITER 
VD — SENIOR WEB CONSULTANT 
SOCIAL MEDIA BUYING — DEG 
WEB MAINTENANCE DG SANTE 
WEBSITES — DEG 
VM — WEB DESIGNER 
GC — WEB DESIGNER 
DG SANTE WEBSITES MAINTENANCE 
PURCHASE OF PROMOTIONAL 

63 

600 000,00 

Amount 
committed 
400 000,00 

40 000,00 

23 490,00 

1 090 000,00 

1 553 490,00 

Amount 
committed 
45 000,00 

15 000,00 

4 307,25 

2 711,31 

30 755,14 

6 084,83 
23 200,00 
10 400,00 
10 000,00 
6 000,00 
24 960,00 
10 944,11 
6 016,33 

32 000,00 
25 000,00 
134 100,00 
2 147,23 

 
 
 
 
 
 
 
  
 
 
 
 
 
 
SANTE/2017/02/074 - 
B3 - 17030100 — 
SANTE/2017/B3/066 - 

SC 6384 — CF - 

SC 7466 — PS - 

SC 7466 - 

SC 7466 - 

SC 9983 - 

SC 1379 - 

OF 3600 - 

SC 10513 

OF 20240 

SC 10532 - 

SC 10532 - 

SC 10532 - 

SC 10532 - 

SC 10532 - 

SC 10485 

SC 10514 - 

SC 10514 - 

SC 10531 - 

SC 10531 - 

SC 10531 - 

MATERIAL FOR DG SANTE — DEG 
SUBTITLING OF 5 VIDEO REPORTAGES 
— CELER PAWLOSWSKY — DEG 
COMMUNICATION ACTIONS IN 2018 ON 
THE NEW MFF 
A4 — IT PUBLIC HEALTH 2017 
PROJECT MANAGER FOR HEALTH 
PROJECTS + AV1 — MOD BA — 
DEGAGEMENT 
PROJECT MANAGER FOR IT HEALTH + 
AV1 + AV2 
PS — PROJECT MANAGER FOR IT 
HEALTH + AV1 + AV2 
PS — PROJECT MANAGER FOR IT 
HEALTH + AV1 + AV2 
CD — APPLICATION ARCHITECT FOR 
PUBLIC HEALTH — AV1+AV2 
DD — TECHNICAL CONSULTANCY 
ENGINEERING SPECIALIST FOR 
ORACLE 
NEW IT LICENSES + RENEWAL & 
MAINTENANCE 
- SJ — PROJECT MANAGER FOR 
DEMATERIALISATION + AV 1 
- SSL CERTIFICATES FOR EUROPEAN 
REFERENCE NETWORK 
BK — PROJECT MANAGER FOR 
HEALTH SYSTEMS 
BK — PROJECT MANAGER FOR 
HEALTH SYSTEMS 
BK — PROJECT MANAGER FOR 
HEALTH SYSTEMS 
BK — PROJECT MANAGER FOR 
HEALTH SYSTEMS 
BK — PROJECT MANAGER FOR 
HEALTH SYSTEMS 
 NT — WEB OPERATION MANAGER 
FOR QUALITY TEAM 
SM — APPLICATION ARCHITECT FOR 
HEALTH & FOOD 
SM — APPLICATION ARCHITECT FOR 
HEALTH & FOOD 
PS — PROJECT MANAGER FOR 
HEALTH — COMPL 
PS — PROJECT MANAGER FOR 
HEALTH — COMPL 
PS — PROJECT MANAGER FOR 
HEALTH — COMPL 

64 

9 991,66 

12 500,00 

123 142,71 
7 000,00 

6 000,00 

6 000,00 

7 000,00 

48 539,41 

31 000,00 

6 176,58 

32 000,00 

2 843,28 

50 000,00 

15 000,00 

55 000,00 

15 000,00 

19 860,00 

18 116,00 

45 000,00 

44 038,70 

75 000,00 

55 000,00 

42 672,00 

 
 
 
 
SC 10622 - 

SC 10489 - 

SC 10489 - 

SC 10624 - 

OF 3690 - 

SC 10609 - 

SC 10609 - 

SC 10582 - 

SC 10529 - 

SC 10529 - 

SC 10824 - 

SC 10509 - 

SC 10509 

SC 9975 — CAN->AA 

SC 9972 - 

OF 3966 - 
OF 3966 - 
SC 190 - 

SC 8529 - 

SC 11954 — RG - 

SC 11468 - 
SC 11468 - 
SC 11471 — PDG - 

SC 11471 — PDG - 

SC 11466 — CC+LV+JPB 
- 

MF — JAVA ARCHITECT FOR FOOD 
FRAUD & MSREP 
CF — PROJECT MANAGER FOR 
HEALTH AND FOOD  
CF — PROJECT MANAGER FOR 
HEALTH AND FOOD  
CBT — BUSINESS INTELLIGENCE 
CONSULTANT FOR FOOD & HEALTH 
SYSTEMS 
RENEWAL MAINTENANCE MISC 
SOFTWARES 
PP — SECURITY & QUALITY 
CONSULTANCY SERVICES 
PP — SECURITY & QUALITY 
CONSULTANCY SERVICES 
DB — ARCHITECT CONSULTANCY FOR 
MEDICINAL PRODUCTS 
AL — INTERFACE DESIGNER FOR 
SANTE PROJECTS 
AL — INTERFACE DESIGNER FOR 
SANTE PROJECTS 
MF — PROJECT MANAGER FOR FOOD 
SAFETY & PUBLIC HEALTH 
CB — DATABASE DEVELOPER FOR 
SAAS2 
CB — DATABASE DEVELOPER FOR 
SAAS2 
DATABASE DEVELOPER 
CONSULTANCY SERVICES FOR DB 
TEAM — MOD PREST + FDI 
UL — DATABASE DEVELOPER FOR 
PLATFORMS — AV1 
NEW IT LICENSES & MAINTENANCE 
NEW IT LICENSES & MAINTENANCE 
SPECIFIC IT SUPPORT TO POLICIES 
(CD) 
MTC — PROJECT MANAGER FOR E-
HEALTH — AV1 
SQL DEVELOPMENT FOR ALL SANTE 
PROJECTS 
EM — SPECIAL APPLICATION SUPPORT 
EM — SPECIAL APPLICATION SUPPORT 
WEB OPERATION MANAGER FOR 
TOBACCO — MOD MT AV1 
WEB OPERATION MANAGER FOR 
TOBACCO — MOD MT AV1 
USER SUPPORT FOR CENTRAL TEAM 
— MOD BL 

65 

48 603,57 

40 649,22 

39 000,00 

44 812,93 

1 456,03 

15 000,00 

25 000,00 

171 668,00 

15 000,00 

38 506,00 

50 000,00 

30 000,00 

35.272.00 

41 447,20 

4 500,00 

524,64 
827,62 
146 156,72 

5 000,00 

56 615,04 

25 000,00 
15 000,00 
64 840,00 

12 116,00 

9 579,80 

 
 
 
 
SC 11826 - 

SC 11826 - 

SC 11826 - 

SC 11826 - 

OF 4430 - 

OF 20328 - 

OF 4453 - 
OF 60 - 
OF 4262 - 

OF 4594 - 

SC 11473 — JG - 
CC, CS100, 2017-50607, 
749974-B21 HP SMART 
ARRAY P440/4GB 
FBWC 12GB 1- 
CC07335, CS013082, 
2017-50676, E-ORDER  
CC06730, CS2896, 2017-
49685,  

CC07445,CS001235 2017-
18860, E-ORDER 
FRAMEWORK 
CONTRACT - 
CC07370, CS8522, 2017-
22427, 

CC07490, CS000062, 
2017-42997 

CC07210, CS1866, 2017-

MTC — PUBLIC HEALTH PHARMA 
SPECIALIST   
MTC — PUBLIC HEALTH PHARMA 
SPECIALIST   
MTC — PUBLIC HEALTH PHARMA 
SPECIALIST 
MTC — PUBLIC HEALTH PHARMA 
SPECIALIST 
RENEWAL OF LICENCE UBSCRIPTIONS 
(CD) 
PURCHASE 4 SINGLE DOMAIN 
CERTIFICATES FOR ORGANISATION 
SSL 3 YEARS 
RENEWAL IDOL ELA LICENCE YEAR 4 
RENEWAL OF APPSCAN SUBSCRIPTION 
DG SANTE PARTICIPATION TO DIGIT 
ELA VMWARE YEAR 1/3 
PURCHASE SOFTWARE FOR 
ACCESSIBILITY TEST TEAM 
DATA ANALYST FOR E_HEALTH 
CANCOM ON LINE -PORT INT SAS 
CONTROLLER — DIGITAL 
WORKPLACE SOLUTION — PURCHASE 

ESP DESIS III — EXTERNAL SERVICE 
PROVISION FOR DEVELOP, STUDIES  
NESTOR II — COMPUTER STORAGE 
EQUIPMENT,RNW MAINTENANCE 
COMLIN (EX OF 2848) — DIGIT DATA 
STORAGE BLOCK 
STIS IVTECHNOLOGY EXPERT (TE) — 
(LEVEL OF EXPERTISE:NORMAL) — 
EXTERNAL AND INTERNAL 
COMMUNICATION — NEXT EUROPA 
* NESTOR III — ACQUISITION OF 
STORAGE HARDWARE WITH 
ASSOCIATED EQUIPMENT, 
MAINTENANCE, UPGRADES AND 
SERVICES. RNW MAINTENANCE DATA 
STORAGE BLOCK (EX OF 8123) PERIOD: 
01/07/2017 - 31/12/2017 
, SOPRA STERIA BENELUX MANAGED 
SERVICES PROVISION (MSP II), BASIC 
SERVICES — CORE SERVICES — 
STARTDATE: 01/12/2017 (UNTIL 
28/02/2018) — MODE SERVICE — BASIC 
SERVICES CORE 
, BECHTLE AG*FWCAPS III LEN 

66 

31 623,64 

39 475,36 

46 552,80 

55 140,00 

17 881,10 

1 843,28 

29 207,80 
3 081,12 
3 274,44 

659,82 

116 518,00 
230 540,80 

3 767,61 

5 572,63 

70 850,00 

277 663,19 

22 547,00 

2 977,92 

 
 
X3650M5 PLUS 8X 6,4CM HDD 
KIT+EXPAN. APSIII STANDARD 
MAINTENANCE 5Y — DIGITAL 
WORKPLACE SOLUTION — PURCHASE 
CANCOM ON LINE 
COMPUTE PLATFORMS — 
VIRTUALISATION HARDWARE 
PURCHASE 

13 216,00 

3 024 473,82 

8 717 409,07 

48572 

CC, CS129, 2017-49137, 
PROVISION OF DATA 
CENTRE COMPUTE 
SOLUTIONS (DCCS) — 
LOT 1- A2S-26SFF-SFP-
AM2 HPE DL380 26SFF 
FC NO HBA —  
Total 

SANTE TOTAL CALLS 
FOR TENDER 

OTHER ACTIONS 

EUR 7 212 500,00  was  earmarked  for  other  actions  in  2017.  Other  actions  cover  the  EU  membership 

contributions  to  the  European  Observatory  on  Health  Systems  and  Policies,  and  —  in  line  with 

Article 121(2)(d)  of  the  Financial  Regulation  —  administrative  agreements  with  the  JRC,  system 

inspections on medicinal products, special indemnities paid to experts for participating in meetings, work 

on  scientific  opinions  and  advice  on  health  systems.  This  also  includes  an  amount  sub-delegated  to 

Eurostat for work on health statistics. 

For more information on specific measures included in ‘other actions’, see the table below. 

Financial instrument  Chafea other actions by objective 
Objective: 
Description of 
objective: 
Thematic priority: 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.7. Foster a health information and knowledge system 
to contribute to evidence-based decision-making 
Title 

Commission membership fee to the European 
Observatory on Health Systems and Policies 

User reference 

2017-European 
Observatory 
Total 

Objectives: 

5.5 Transversal actions  

Thematic priority: 

5.5.1 Evaluators of calls for proposals 

User reference 

Title 

67 

Amount 
committed 

500 000,00 

500 000,00 

Amount 
committed 

 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluators of call for proposals 

Total 

Chafea TOTAL 
OTHER ACTIONS 

Financial instrument  SANTE other actions by objective 
Objective: 
Description of 
objective: 

1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles taking 
into account the ‘health in all policies’ principle 
1.4 Chronic diseases including cancer, age-related 
diseases and neurodegenerative diseases 
Title 

Thematic priority: 

User reference 

C1 — ADMINISTRATIVE ARRANGEMENT 34950 
BETWEEN DG SANTE AND JRC ON HQHDI 
(HEALTH CARE, QUALITY, HEALTH DATA 
INFORMATION)  

Total 

Thematic priority: 

1.5. Tobacco legislation  

User reference 

Total 
Thematic priority: 

User reference 

Title 
B2 — SI2.763420 - 17.030100 AA WITH JRC 
No 34851 — TECHNICAL SUPPORT TO THE 
IMPLEMENTATION OF THE TOBACCO 
PRODUCTS DIRECTIVE 

1.6 Foster a health information and knowledge system 
to contribute to evidence-based decision-making, 
Title 

07154.2017.002-2017.494 / NATIONAL 
STATISTICAL INSTITUTE OF BULGARIA / F.4 
07154.2017.002-2017.493 / STATISTICS AUSTRIA / 
F.4 
07154.2017.002-2017.497 / CROATIAN INSTITUTE 
OF PUBLIC HEALTH / F.4 
07154.2017.002-2017.498 / HUNGARIAN CENTRAL 
STATISTICAL OFFICE / F.4 
07154.2017.002-2017.499 / CENTRAL STATISTICAL 
OFFICE OF POLAND / F.4 
07154.2017.002-2017.501 / STATISTICAL OFFICE 

68 

163 836,33 

163 836,33 

663 836,33 

Amount 
committed 

2 200 000,00 

2 200 000,00 

Amount 
committed 
100 000,00  

100 000,00  

Amount 
committed 
38 958,49 

26 330,35 

30 563,37 

26 134,28 

25 547,23 

54 786,00 

 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
OF THE SLOVAK REPUBLIC / F.4 
07154.2017.002-2017.495 / STATISTICS ESTONIA / 
F.4 
07154.2017.002-2017.496 / DRESS FRANCE / F.4 
07154.2017.002-2017.500 / NATIONAL INSTITUTE 
OF PUBLICHEALTH / F.4 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.4 
Title 

Expert Panel on effective ways of investing in health —  

3.6 
Title 

Medical Device Coordination Group (MDCG) — 
meetings on new regulations and in-vitro diagnostic 
devices by legislators 

25 288,24 

37 500,00 
78 868,36 

343 976,32 

Amount 
committed 
165 000,00 

165 000,00 

Amount 
committed 
95 000,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

15 000,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

1 350 000,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

564,74 

69 

Total 
Objective: 
Description of 
objective: 
Thematic priority: 
User reference 

Indemnities paid to 
experts  
Total 
Thematic priority: 
User reference 

REIMBURSEMENT 
OF EXPERTS 
EXPENSES FOR 
JOINT 
ASSESSMENT ON 
MEDICAL DEVICES 
— 
REIMBURSEMENT 
OF SMALL COSTS 
OTHER THAN 
AMEX — COMPL 
REIMBURSEMENT 
OF EXPERTS 
EXPENSES FOR 
JOINT 
ASSESSMENT ON 
MEDICAL DEVICES 
— AMEX 
EXPENSES 
GROW/D4 — 
ADMINISTRATIVE 
ARRANGEMENT 
WITH JRC ON THE 
IMPLEMENTATION 
OF THE NEW EU 
LEGISLATION ON 
MEDICAL DEVICES 
VICH MEETING 
JULY 2017-1 

 
 
 
 
 
  
 
 
 
 
 
EXPERT 
VICH MEETING 
NOVEMBER 2017 - 
1 EXPERT 
VICH MEETING 
JULY 2017-1 
EXPERT 
2017 ICH MEETING 
— AMEX-
WASHINGTON-
APRIL 
2017 ICH MEETING 
— EXPERTS — DEG 
—  
2017 ICH MEETING 
— CANADA — 
MAY - 
2017 ICH MEETING 
— SWITZERLAND 
— NOVEMBER — 
DEG - 
ICH AND IPRF 
CONTRIBUTION 
FOR 2018 — DEG —  
 JAP AUDIT ON 
GMP — DEG —  
Total 
SANTE TOTAL 
OTHER ACTIONS 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

3 201,34 

69,00 

8 409,39 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

102 800,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

72 144,80 

7 000,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

245 000,00 

MDCG — meetings on new regulations and in-vitro 
diagnostic devices by legislators 

55 000,00 

1 954 189,27 
4 763 165,59 

70 

 
 
 
 
 
 
 
 
 
 
DETAILED OVERVIEW OF THE REPORTING YEAR 2017 

Funding per thematic priority and financial instrument 

Objective: 

1 

Description of 
objective: 

1. Promote health, prevent diseases and foster supportive environments for healthy lifestyles taking into account the ‘health in all policies’ 
principle 

Third health 
programme 
thematic 
priorities 

Chafea 
projects 
grants by 
objective 

Chafea 
ERN 
actions 
SGAs 
under FPA 
by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements 
by objective 

Chafea 
presidency 
conferences 
by objective 

Chafea calls 
for tender by 
objective 

SANTE calls for 
tender by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

1.1 Cost-effective 
promotion and 
prevention 
measures on 
alcohol and 
nutrition … 
1.2 Drugs-related 
health damage, 
information and 
prevention 

0.00 

0.00 

2 536 592,80 

2 499 997,02 

1 000 000,00 

210 059,00 

2 732 009,00 

686 500,00 

0.00 

0.00 

9 665 157,82 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

71 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Support 
effective 
responses to 
communicable 
diseases, 
HIV/AIDS, 
tuberculosis and 
hepatitis … 

1.4 Chronic 
diseases, cancer, 
age-related 
diseases and 
neurodegenerativ
e diseases 
1.5. Tobacco 
legislation 

1.6 Foster a 
health 
information and 
knowledge 
system to 
contribute to 
evidence-based 
decision-making 
Total 

0.00 

0.00 

619 415,60 

0.00 

0.00 

0.00 

248 910,00 

0.00 

0.00 

0.00 

868 325,60 

0.00 

0.00 

775 680,00 

4 500 000,00 

0.00 

0.00 

0.00 

0.00 

0.00 

2 200 000,00 

7 475 680,00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3 100 000,00 

0.00 

0.00 

534 338,00 

195 000,00 

0.00 

100 000.00 

829 338,00 

0.00 

0.00 

0.00 

343 976,32 

3 443 976,32 

0.00 

0.00 

3 931 688,40 

6 999 997,02 

4 100 000,00 

210 059,00 

3 515 257,00 

881 500,00 

0.00 

2 643 976,32 

22 282 477,74 

Objective: 

2 

Description of 
objective: 

2. Protect EU citizens from serious cross-border health threats 

72 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Third health 
programme thematic 
priorities 

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA 
by objective 

Chafea 
operating 
grants by 
objective 

Chafea 
joint 
actions by 
objective 

0.00 

0.00 

0.00 

0.00 

Chafea 
direct grant 
agreements 
by 
objective 

0.00 

Chafea 
presidency 
conferences by 
objective 

Chafea calls 
for tender by 
objective 

SANTE calls 
for tender by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

2.1 Improve risk 
assessment and close 
gaps in risk 
assessment 
capacities … 

2.2 Support capacity-
building against 
health threats in 
Member States 

Total 

0.00 

0.00 

0.00 

6 530 231,97 

0.00 

0.00 

668 318,00 

0.00 

0.00 

0.00 

7 198 549,97 

0.00 

0.00 

0.00 

6 530 231,97 

0.00 

0.00 

668 318,00 

0.00 

0.00 

0.00 

7 198 549,97 

73 

 
 
 
 
 
 
Objective: 

3 

Description of 
objective: 

3. Contribute to innovative, efficient and sustainable health systems 

Third health 
programme thematic 
priorities 

Chafea projects 
grants by 
objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea 
direct grant 
agreements 
by objective 

Chafea 
presidency 
conferences 
by objective 

Chafea       
calls for tender 
by objective 

SANTE 
calls for 
tender by 
objective 

Chafea 
other 
actions by 
objective 

SANTE 
other 
actions by 
objective 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

113 035,70 

0.00 

0.00 

0.00 

113 035,70 

0.00 

0.00 

0.00 

2 699 989,67 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

2 699 989,67 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

600 000,00 

0.00 

0.00 

39 945,25 

0.00 

165 000,00 

804 945,25 

3.1 Support voluntary 
cooperation between 
Member States on 
health technology 
assessment … 

3.2 Promote the 
voluntary uptake of 
health innovation and 
e-Health by increasing 
the interoperability of 
patient registries and 
other e-Health 
solutions 
3.3 Support the 
sustainability of the 
health workforce by 
developing effective 
health workforce 
forecasting and 
planning  

3.4. Provide expertise 
and share good 
practices to assist 
Member States 
undertaking health 
system reforms … 

74 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.00 

0.00 

250 000,00 

0.00 

3 300 000,00 

0.00 

520 000,00 

2 618 000,00 

0.00 

1 954 189,27 

8 642 189,27 

0.00 

0.00 

0.00 

3 999 191,48 

700 000,00 

0.00 

0.00 

600 000,00 

500 000,00 

0.00 

5 799 191,48 

3.6 Implementation of 
EU legislation in the 
field of medical 
devices, medicinal 
products and cross-
border health care 

3.7. Foster a health 
information and 
knowledge system to 
contribute to 
evidence-based 
decision-making 

Total 

0.00 

0.00 

0.00 

6 699 181,15 

4 600 000,00 

0.00 

633 035,70 

3 257 945,25 

500 000,00 

2 119 189,27 

18 059 351,37 

75 

 
 
 
 
 
Objective: 

Description of 
objective: 

4 

4. Facilitate access to better and safer healthcare for EU citizens 

Third health 
programme thematic 
priorities 

Chafea projects 
grants by 
objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea 
direct grant 
agreements 
by objective 

Chafea 
presidency 
conferences 
by objective 

Chafea  
calls for tender 
by objective 

SANTE  
calls for 
tender by 
objective 

Chafea 
other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

4 504 311,91 

0.00 

0.00 

0.00 

0.00 

272 541,75 

1 553 490,00 

0.00 

0.00 

6 330 343,66 

0.00 

0.00 

1 325 613,00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1 325 613,00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

600 000,00 

0.00 

0.00 

0.00 

0.00 

0.00 

600 000,00 

4.1 Support the 
establishment of a 
system of European 
reference networks for 
patients with 
conditions requiring 
highly specialised 
care … 
4.2 Coordinated action 
at EU level in order to 
effectively help 
patients affected by 
rare diseases 

4.3 Strengthen 
collaboration on patient 
safety and quality of 
health care 

4.4 Improve the 
prudent use of 
antimicrobial agents 
and reduce the 
practices that increase 
antimicrobial resistance 

76 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Implementation of 
EU legislation in the 
fields of human tissues 
and cells, blood, human 
organs, medical 
devices, medicinal 
products, and patients’ 
rights in cross-border 
health care 
Total 

0.00 

0.00 

304 611,00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

304 611,00 

0.00 

4 504 311,91 

1 630 224,00 

0.00 

600 000,00 

0.00 

272 541,75 

1 553 490,00 

0.00 

0.00 

8 560 567,66 

77 

 
 
 
 
 
 
 
Objective: 

5 

Description of objective: 

5. IT / dissemination (Horizontal –transversals action related to all objectives)  

Third health 
programme thematic 
priorities 

Chafea projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

horizontal IT / 
dissemination/evaluation 
call for proposals 
Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

Chafea 
direct 
grant 
agreements 
by 
objective 

0.00 

Chafea 
presidency 
conferences 
by 
objective 

Chafea  
calls for 
tender by 
objective 

SANTE calls 
for tender by 
objective 

Chafea other 
actions by 
objective 

Total 

SANTE 
other 
actions 
by 
objective 

0.00 

773 921,23 

3 024 473,82 

163 836,33 

0.00 

3 962 231,38 

0.00 

0.00 

0.00 

0.00 

773 921,23 

3 024 473,82 

163.836,33 

0.00 

3 962 231,38 

TOTAL ACTIONS COMMITTED BY CHAFEA UNDER AWP 2017 

TOTAL ACTIONS COMMITTED BY DG SANTE UNDER AWP 2017 

TOTAL COMMITTED  

46 582 603,46 

13 480 574,66 

60 063 178,12 

78